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 ABSTRACT 
 
Migration within the European Union (EU) has increased since the Union was 
established. Community pharmacies provide open access to health care services and 
can be the first, most frequently used or even the only contact with a nation’s health care 
system among mobile community residents. In some of the mass-migration areas in 
Southern Europe, most of the customers may represent mobile citizens of foreign 
background.  This has not always been taken into consideration in the development of 
community pharmacy services. Mobile patients have been on the EU's health policy 
agenda, but they have seldom been mentioned in the context of community pharmacies. 
In most of the EU member states, governments control the specific legislation concerning 
community pharmacies and there is no harmonised pharmaceutical policy or consistent 
minimal standards for community pharmacy services in the EU. 
    The aim of this study was to understand medication use, the role of community 
pharmacies and the symptom mitigation process of mobile community residents. Finns 
living in Spain were used as an example to examine how community pharmacies in a EU 
member state meet the needs of mobile community residents. The data were collected by 
a survey in 2002 (response rate 53%, n= 533) and by five focus group discussions in 
2006 (n=30). 
    A large number (70%) of the respondents had moved to Spain for health reasons and 
suffered from chronic morbidity. Community pharmacies had an important role in the 
healthcare of mobile community residents and the respondents were mostly satisfied with 
these services. However, several medication safety risks related to community pharmacy 
practices were identified: 1) Availability of prescription medicines without prescription 
(e.g., antibiotics, sleeping pills, Viagra®, asthma medications, cardiovascular medicines, 
psoriasis medicines and analgesics); 2) Irrational use of medicines (e.g., 41% of antibiotic 
users had bought their antibiotics without a prescription, and the most common reasons 
for antibiotic self-medication were symptomatic common colds and sore throats); 3) 
Language barriers between patients and pharmacy professionals; 4) Lack of medication 
counselling; 5) Unqualified pharmacy personnel providing pharmacotherapy. A fifth of the 
respondents reported experiencing problems during pharmacy visits in Spain, and the 
lack of a common language was the source of most of these problems. 
    The findings of this study indicate that regulations and their enforcement can play a 
crucial role in actually assuring the rational and safe use of medicines. These results can 
be used in the development of pharmaceutical and healthcare policies in the EU. It is 
important to define consistent minimum standards for community pharmacy services in 
the EU.  Then, the increasing number of mobile community residents could access safe 
and high quality health care services, including community pharmacy services, in every 
member state within the EU  
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 DEFINITIONS OF THE KEY CONCEPTS 
 
Community pharmacy system 
Each EU nation has a unique community pharmacy system reflecting the culture 
and history of the country.  It is built to comply with the local laws and regulations. 
There are similarities in regulations between the member states, but the specific 
legislation on these services contains differences between pharmacy systems in 
member states. The differences between the member states occur in e.g. the 
pharmacies´ role as a distributor of medicine, the number of outlets per 1,000 
inhabitants and the rules governing establishment, ownership and staff (Vogler et 
al. 2006). In this thesis, the terms "pharmacy system" or "community pharmacy 
system" are used in this context. 
 
European Union 
The European Union (EU) was established by six states in 1958, and now EU 
comprises 27 countries and 490 million people (Europa 2006a). The basic 
principles of the Union are to facilitate the free movement of goods, services, 
capital and citizens (Treaty establishing the European Community 2002).  
 
European Union legislation 
Community legislation is based on treaties, which act as the primary legislation. 
The secondary legislation is based on the treaties and is incorporated into 
regulations, directives, decisions, recommendations and resolutions.  From these, 
regulations are binding as specifically described, directives are binding in their 
respective context and decisions are binding for the addressed parties. 
Recommendations and resolutions are legally non-binding 
(http://europa.eu.int/eur-lex). 
 
Health immigrant 
A person who indicates that health factors play a moderate or significant role in 
the migration process is categorised as a health immigrant.  
 
 
Mobile patient 
Community law provides EU citizens with the right to seek healthcare in other 
member states. When mobile community residents use health services in other 
member states, they can be called "mobile patients" (European Commission 
2004). 
 
 
 
  
 
Mobile community resident; Mobile citizen; Migrant 
In this thesis, the terms listed above are used to describe people who move from 
one country to another. Some of these people reside permanently in the foreign 
country, but most of these people, especially those who move within the 
European Union, spend one part of the year in the foreign country and another 
part in their country of origin.  
 
National drug policy 
A national drug policy defines and sets forth medium and long-term goals for the 
pharmaceutical sector and sets up the strategies to reach the goals (WHO 2001). 
 
Pharmaceutical policy 
Pharmaceutical policy sets up the principles that guide pharmaceutical 
policymaking. It is a plan or a course of actions that influence, guide or determine 
present and future decisions in the pharmaceutical sector.  
 
Self-medication 
The term "self-medication" is used to describe the practice of consumers using 
medicines without consulting a physician. Self-medication may take place with 
either prescription or non-prescription medicines (undesirable self-medication). 
 
Symptom mitigation path 
Symptom mitigation path describes the possible actions that may be taken prior to 
the person with the symptoms receiving instructions on how to manage the 
condition. In this particular study, symptom mitigation path describes the 
sequence of alternative events, which may occur when a symptomatic mobile 
community resident uses community pharmacy services. 
 ABBREVIATIONS 
 
ADD= Automated Dose Dispensing 
AFP = The Association of Finnish Pharmacies 
DRP = Drug related problem 
E-form = A form (e.g., E111, E128) which enabled people to obtain health 
services in a foreign EU-country. E-forms are replaced by EHIC card (European 
Commission 2003a).  
ECJ = European Court of Justice 
EHIC = European Health Insurance Card 
EMEA = European Medicines Agency 
EU = European Union  
FIP = International Pharmaceutical Federation 
GP = General practitioner 
HAI = Health Action International  
IT = Information technology 
NAM = National Agency for Medicines  
OECD = Organisation for Economic Cooperation and Development 
OTC = Over-the-counter medicine 
PCNE = Pharmaceutical Care Network Europe 
PGEU= Pharmaceutical Group of the European Union. A European association 
that represents community pharmacies.  
Rx = Prescription medicine 
SIDA = Swedish International Development Cooperation Agency 
TIPPA Project = A four-year national project to implement national professional 
strategy in Finnish community pharmacies with a special emphasis on patient 
counselling. 
WB = World Bank 
WHO = World Health Organization 
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1 INTRODUCTION 
 
 
The European Union (EU) was created by six states in 1958 in order to establish 
a common European market. In the beginning of 2007, the EU enlarged by two 
member states, thereafter comprising 27 member states and a population of up to 
half a billion (Europa 2006a). The basic principles of the Union are to facilitate the 
free movement of goods, services, capital and citizens (Treaty establishing the 
European Community 2002).    
 
Migration within the EU has increased since the Union was established, and to 
date, thousands of people from different backgrounds have taken advantage of 
the possibilities for free movement. Many of these people work abroad, but 
another increasing trend is retirement migration (King et al. 1998). People from 
Northern European countries in particular are becoming permanent or part-time 
residents of Southern European countries where living costs are lower and the 
climate more moderate (Rosenmöller and Lluch 2006). Meeting the health service 
needs of this heterogeneous migrant population poses a challenge to the 
authorities in countries with high immigration rates – particularly if the people are 
not assimilated into that society. This situation will intensify as the number of EU 
member states and mobile community residents continue to increase (Europa 
2006a). 
 
In the EU, the responsibility for organising and delivering healthcare services, 
including community pharmacy services, is the responsibility of individual member 
states (Treaty of Amsterdam 1997, Article 152, Directive 2005/36/EC). On the 
other hand, the EC Treaty states that there should not be any barriers to the free 
establishment of services (Article 43) and that services should be allowed to be 
provided freely across the borders (Articles 49 and 50). Member states wish to 
maintain their responsibilities in the field of health services, and in many cases, 
conflicts relating to this have been settled in the European Court of Justice (ECJ) 
(Neroth 2005). ECJ rulings have shown that healthcare services are not merely a 
matter for member states, and that the balance between the competencies of 
member states and the EU is not always clear (Hämäläinen et al. 2004). The EU 
deals with two distinct objectives when it comes to healthcare policies, including 
pharmaceutical policy: it has to ensure public health and to promote a single 
market (Wahlroos 2003). There have often been intentions in the EU of promoting 
better provisions in the internal market, and in 2004 the first version of the 
Services Directive was announced in order to ensure that companies offering 
services might operate freely in all member states (European Commission 
2005b). In the first phase, healthcare services were included in the proposal 
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(European Commission 2005b). The inclusion of healthcare services in this 
directive would have increased competition in the field of health services, but it 
would have also affected member states' ability to plan their service provision 
(Neroth 2005). The proposal aroused criticism as being contradictory with the EU 
Treaty and as being open to interpretation (Kärkkäinen 2005). As a consequence, 
healthcare services were excluded from the final directive (Directive 
2006/123/EC). However, the legislation concerning internal markets and EJC 
rulings have had a great influence on the healthcare services (Hämäläinen et al. 
2004). 
 
 Community pharmacies provide open access to health care services and can be 
the first, most frequently used or even the only contact an immigrant has with a 
nation’s health care system. As pharmacy services play an essential role in 
primary health care, it is important that these services meet the different needs of 
their customers. In some of the mass-tourism and migration areas of Southern 
Europe, most of the customers are mobile citizens, that is, foreign nationals. This, 
however, has not always been taken into consideration in the development of 
pharmacy services. Even though mobile patients have been on the EU’s health 
policy agenda (European Union 2006), they have seldom been mentioned in the 
context of community pharmacy services.  However, pharmacy systems should be 
able to offer high quality as well as safe and effective services to all of their 
customers. At the moment, there is no harmonised pharmaceutical policy in the 
EU concerning community pharmacy practices. These practices differ between 
member states and the regulations and control over rational use of medicines and 
self-medication are not similarly interpreted in different countries (Vogler et al. 
2006). It has been argued that the different practices between member states 
restrict cross-border healthcare (Mäkinen 2008). Pharmaceutical policy is not 
greatly studied from a community-pharmacy and health-services perspective. 
National and EU policymaking is focused on pharmaceuticals and on the costs 
they cause to the society.  
 
As groundwork for this thesis, I have conducted a systematic search and reading 
of documents and scientific papers that are linked with pharmaceutical policy in 
Europe and in the EU. In the data gathering, I have used the electronic databases 
PubMed (including Medline), International Pharmaceutical Abstracts (IPA) and 
Medic as well as the online search engine Google. In addition, I have searched 
documents from the web pages of international organisations, such as the EU and 
WHO. In the first part of the literature review of this thesis, the key pharmaceutical 
policy documents are reviewed and, based on them, pharmaceutical policy is 
described: what it is, how it is developed and what influence it has on different 
stakeholders within the EU framework. The influence of pharmaceutical policy on 
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the role of community pharmacists is reviewed in more detail. Community 
pharmacy practices and patient self-medication are an essential part of this study, 
and they are examined in the following chapters as both are influenced by 
pharmaceutical policymaking.  In pharmaceutical policy papers, it is often the case 
that less attention is paid to community pharmacy services and patient self-
medication, though both are connected with important parts of pharmaceutical 
policy as they involve access to medicines, rational use of medicines, medication 
safety and drug expenditure. 
 
The final part of the literature review provides the context for this study and 
introduces migrants and mobile patients. By using Finns living in Spain as an 
example, this study examines how mobile community residents experience the 
provision of pharmacy services in the EU. The aim of the study is to understand 
medication use and the role of community pharmacies in the symptom mitigation 
process from the perspective of how a pharmacy system and different state 
regulations affect medicine use, rational pharmacotherapy and medication safety. 
This is one of the first studies in the EU to focus on mobile community residents’ 
use of community pharmacy services in their new countries of residence. The 
results of this study will provide information for the implementation of the EU 
pharmaceutical policy for mobile community residents and mobile patients.  
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2 PHARMACEUTICAL POLICY 
 
 
2.1 What is pharmaceutical policy? 
 
According to Almarsdottir and Traulsen (2006): “Pharmaceutical policy deals with 
the principles guiding decision-making in the field of pharmaceuticals. The goal of        
pharmaceutical policy is (similar to other social policy) to contribute to the overall 
health, welfare and well being of society. It includes any policy that attempts to 
improve or regulate registration, reimbursement, and distribution of 
pharmaceuticals”.  
 
Mossialos et al. (2004) list the intended effects of pharmaceutical policy as 
follows: 
 
• Improved access to cost-effective medicines 
• Minimisation of health risks 
• Reduced drug over-utilisation  
• Containment of expenditure growth 
 
According to WHO (2001): ”A national drug policy is a commitment to a goal and a 
guide for action. It expresses and prioritises the medium- to long-term goals set by 
the government for the pharmaceutical sector, and identifies the main strategies 
for attaining them” (WHO 2001). 
 
National pharmaceutical policy is a formal document that directs co-operators to 
make decisions (WHO 2001). A national pharmaceutical policy lists the aims, 
decisions and commitments that the involved parties aspire to and commit to 
implement in the future (WHO 2001).  National pharmaceutical policies might 
have different objectives, but generally pharmaceutical policies aim to ensure 
access, quality and rational use of medicines (WHO 2001). As most countries are 
experiencing rising drug expenditures, controlling these expenditures has become 
one of the major objectives of pharmaceutical policies (Jacobzone 2000).  
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2.2 Key pharmaceutical policy documents and research 
 
As the power of the drug industry and the use of industrially manufactured 
medicines has increased, the interest in pharmaceutical policies has increased 
worldwide. As a consequence, pharmaceutical policy is found on the agendas of 
international organisations such as the EU, WHO, OECD and World Bank (WB). 
This section describes the key pharmaceutical policy documents. Most of the 
pharmaceutical policy documents concentrate on drug expenditures and on the 
role of pharmaceutical policies in reducing these expenditures. They seldom 
address policies concerning community pharmacies and their role in reducing 
medicine costs, promoting rational use of medicines and medication safety.  
 
2.2.1 Pharmaceutical policy in the European Union 
 
European Pharmaceutical policymaking has always had a dual objective: to 
ensure public health and to promote the competitiveness of the industry 
(European Commission 2007a). In the European Community, the pharmaceutical 
policy work was started as early as 1965 with the first European Community 
directive on pharmaceuticals (Council Directive 65/65/EEC). At that time, the 
focus of the policymaking was on public health perspectives as the thalidomide 
catastrophe was influencing the preparation of the directive, and the main 
objective of the directive was to ensure that medicinal products for human use 
would help maintain the high level of protection of public health and prevent the 
reoccurrence of such a disaster (European Commission 2000a). However, 
already in the 1960s pharmaceutical policymakers had their sights on the free 
movement of pharmaceuticals within the Community, and the European 
Pharmacopoeia was founded to improve the trade by harmonising the 
manufacturing and quality control standards in the Community area (Stainier 
1975, European Commission 2000b).  In 1970s the preparation of more 
centralised marketing authorisation procedures was started and the Committee for 
Proprietary Medicinal Products (CPMP) was established by Council Directive 
75/319/EEC and Council Decision 75/320/EEC. At the same time, requirements 
were introduced concerning the content of marketing authorisation application 
dossiers (Lisman and Lekkerkerker 2005). By these directives, the important 
steps towards creating a is single market for pharmaceuticals were taken, and 
since 1985, many community directives have been adopted with the aim of 
promoting a single market of pharmaceuticals (European Commission 2000a). In 
1987, the first European marketing authorisation procedure was introduced 
(Council Directive 87/21/EEC). In the beginning of 1990, the rational use of 
medicines was an important pharmaceutical issue and the “rational use of 
medicines” package of directives was introduced (European Commission 2000b). 
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One remarkable development in the process towards more harmonious 
pharmaceutical policy in EU was the creation of the European Medicines 
Evaluation Agency in 1995. The establishment of the EMEA introduced new 
marketing authorisation procedure - the Centralised Procedure – which enabled 
patients to have faster access to innovative pharmaceutical products within the 
Community (Lisman and Lekkerkerker 2005). EMEA evaluates the safety, efficacy 
and quality of the medicinal products, and since its establishment, EMEA has 
offered scientific advice, harmonised drug information practices (SPCs, PILs and 
labelling) and improved transparency and pharmacovigilance practices (Garattini 
and Bertele 2001, Li Bassi et al. 2003, Garattini and Bertele 2004).  
 
At the moment, the EU’s pharmaceutical policy mainly follows the 
recommendations of the High Level Group on Innovation and Provision of 
Medicines – G10 Medicines. This group was set up in 2000 with the aim of 
determining how pharmaceutical, health care and business policies could achieve 
two distinct goals: to improve competitiveness and to encourage health protection 
(European Commission 2002a). The final report included 14 recommendations 
and most of which concentrated on developing the competitiveness of the 
pharmaceutical industry (European Commission 2003b).  Public health issues 
were also addressed in a recommendation to enhance medicine information and 
to improve the pharmacovigilance system (European Commission 2003b). In 
2005, the Commission created the Pharmaceutical Forum in order to continue the 
process around three key themes: information to patients on pharmaceuticals, 
pricing policy and the relative effectiveness of medicines (Pharmaceutical Forum 
2007). 
 
The future challenges for the pharmaceutical policymaking concern the 
globalisation of the pharmaceutical sector, functioning internal markets and the 
advantages provided by science and technology (European Commission 2007a). 
Globalisation brings more actors into the pharmaceutical sector, leading to an 
increase in competition, both in the field of pharmaceutical innovations and in 
business. Removing the barriers to a better functioning internal market has been 
seen as important to increasing the competitiveness of European actors. Although 
there are harmonised procedures in the field of marketing authorisations, the 
different national pricing and reimbursement systems pose challenges for 
pharmaceutical policymakers. Improving the safety of the medicines in the EU 
while not affecting patient access to medicines is also seen as challenging 
(European Commission 2007b). Counterfeit medicines may be mentioned as one 
of the safety threats that makes the policymaking challenging.  
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2.2.2 Pharmaceutical policy and international organisations 
 
The WHO has published several publications concerning pharmaceutical policy 
(WHO 2001, 2004a). In 1988, WHO published “Guidelines for Developing 
National Drug Policies”, which has been updated and replaced by the publication 
“How to develop and implement a national drug policy” (WHO 2001). This work 
has been extended with “Medicines strategy in 2004” (WHO 2004a).  
 
Similarly, the OECD has studied pharmaceutical policy and has found the tasks 
involved challenging because of its dualistic nature to be in the middle of industrial 
and health policy goals (Jacobzone 2000). It is challenging for policymakers and 
governments to find a balance between rising pharmaceutical expenditures and 
the benefits resulting from the use of pharmaceuticals. A new discipline, 
pharmacoeconomics, studies ways of finding this kind of balance (Bootman et al. 
2006). Even though the OECD has studied pharmaceutical policies in OECD 
countries, more research in areas that concern community pharmacy services is 
still required (Jacobzone 2000).   
 
In recent years, the WB became one of the most important actors in the field of 
pharmaceuticals and international health care in low- and middle-income 
countries (Falkenberg and Tomson 2000).  After the publication of the WB 
development report in 1993, there were subsequent studies that examined World 
Bank loans and questioned their commitment to their stated pharmaceutical policy 
(Falkenberg and Tomson 2000, Homedes et al. 2005, Rodriguez-Monguio and 
Rovira 2005). The World Bank is the largest source of loans in the field of health 
care and pharmaceuticals in low and middle-income countries, but the study of 
Falkenberg and Tomson (2000) argues that only a small percentage of its loans 
have been directed to drug policy or to promote the rational use of medicines. 
Therefore, they argue that pharmaceuticals should have larger role in World Bank 
projects and that more research in the field of pharmaceutical policy is required.  
 
2.2.3 European co-operation in pharmaceutical policy work 
 
European Observatory on Health Systems and Policies is an international project 
that aims to improve healthcare systems in Europe. The partners of this project 
include the WHO Regional Office in Europe; the Governments of Belgium, 
Finland, Greece, Norway, Spain and Sweden; the European Investment Bank; the 
Open Society Institute; the World Bank; the London School of Economics and 
Political Science; and the London School of Hygiene & Tropical Medicine. As a 
part of this project, Mossialos et al. (2004) published the pharmaceutical policy 
 20 
work ”Regulating pharmaceuticals in Europe: striving for efficiency, equity and 
quality”. This book describes different approaches that governments and 
regulators have used to manage pharmaceutical policy and spending in different 
European countries. It describes how pharmaceuticals, prices and 
reimbursements are regulated and managed in the EU and what is the role of 
European Medicines Agency (EMEA). The book also contains information about 
prescription practices, patients and their medicines as well as it describes 
European drug distribution systems and community pharmacies (Mossialos et al. 
2004). The main objective of the book, however, is to consider different 
approaches to manage pharmaceutical expenditures. 
 
2.2.4 Pharmaceutical policy in Finland 
 
In Finland, Ministry of Social Affairs and Health launched the first pharmaceutical 
policy paper in the history of the country (Ministry of Social Affairs and Health 
2003). The aim of the paper was to define the most important objectives for 
national pharmaceutical policy until 2010. The main objective was to maintain the 
high level of medication safety in Finland and to secure access to medicines 
throughout the country. In this context it was stated that the sale of medicines 
(including OTC medicines) would continue to take place in pharmacies in the 
future. The paper promoted rational prescribing and use of medicines. The 
importance of professionally skilled staff, medication counselling and drug 
information was emphasised as well.  The increase in drug expenditures was 
noted, and it was suggested that costs could be reduced by cutting down the 
pharmacies’ gross-margin of sales and by reforming the drug reimbursement 
system. It was also suggested that Finland should take a more active role in EU 
cooperation on this issue and that the development of new medical products and 
pharmacotherapies should be promoted. In 2008, Mossialos and Srivastava 
prepared at the request of the Health Department, Ministry of Social Affairs and 
Health, a policy review of the regulatory system of Pharmaceutical policies in 
Finland (Mossialos and Srivastava 2008). 
 
2.2.5 Research on pharmaceutical policy in Europe 
 
Little research has focused on pharmaceutical policy in Europe. Traulsen and 
Almarsdottir have published an article series on pharmaceutical policy 
(Almarsdottir and Traulsen 2005a-b, 2006, Traulsen and Almarsdottir 2005a-c). In 
contrast to the policy work of most of the international organisations, they have 
studied pharmaceutical policy from a community-pharmacy perspective 
(Almarsdottir and Traulsen 2005a-b, 2006, Traulsen and Almarsdottir 2005a-c). 
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This reflects the fact that, in Scandinavian countries, deregulation of pharmacy 
systems has been a hot topic since the mid-1990’s, especially in Denmark, 
Iceland and Norway (Morgall and Almarsdottir 1999, Anell 2005, Noerreslet et al. 
2005, Larsen et al. 2006, Vogler et al. 2006). The market deregulation of OTC 
drugs has been studied in Germany also (Stargardt et al. 2007). In Finland, 
Wahlroos (2003) conducted an extensive document analysis on how decision-
making in the EU seeks a balance between internal market goals and public 
health, and how these decisions influence pharmaceutical legislation and patient 
information. Generally, the research in pharmaceutical policy within the EU has 
mainly followed themes similar to those emphasised by the G10 group in their 
report. Based on their review of the literature the focal point of recent European 
studies has been on pharmaceutical cost and reimbursement systems, access to 
pharmaceuticals, and pharmaceutical regulation (Mossialos et al. 2004, Cohen et 
al. 2006, Permanand et al. 2006, Cohen et al. 2007, Garattini et al. 2007, 
Mossialos and Srivastava 2008).  
 
The pharmaceutical policies of international organisations examine 
pharmaceuticals from the perspective of the industry (product safety, quality) and 
of governments (access to medicines and drug expenditures). Although WHO 
promotes the rational use of medicines, retail sales of medicines and their use in 
health care have received less attention in its pharmaceutical policy papers.  
Retail sales outlets and community pharmacies are often seen as third parties 
when it comes to the development of health care and pharmaceutical policies 
(Kuusi et al. 2006). Active debate within the pharmaceutical community has 
resulted in very few attempts to influence actual policymaking. The 
pharmaceutical community is not accustomed to being a partner and to 
influencing society-wide matters on health care or medication. This can also be 
seen within the political decision-making process. For example, in the Finnish 
Ministry of Social Affairs and Health there is no professional expertise in the 
pharmaceutical sector involved in preparing pharmaceutical policies or in 
evaluating the influences of these policies.  
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2.3 Key areas included in pharmaceutical policy documents 
 
The key objectives of pharmaceutical policy are to ensure access and quality of 
medicines, to promote rational use and to control the rising drug expenditures. 
Table 1 lists the components of pharmaceutical policy and their relation to the key 
policy objectives according to the WHO (2001). Each component of the 
pharmaceutical policy affects one or more objectives. 
 
 
Table 1. Components of a national pharmaceutical policy, linked to key policy 
objectives (Created based on WHO’s table, WHO 2001) 
 
 
 
 
 
 
 
 
 
 
X =direct link; (x) = indirect link 
 
2.3.1 Access to essential medicines and cost-effective medicines 
 
According to WHO (2001): essential medicines are those that satisfy the priority 
health care needs of the population. Availability and affordability of essential 
medicines are important issues in national pharmaceutical policy. Most developed 
country governments have lists of essential medicines that are carefully selected 
and based on clinical guidelines (WHO 2005).  The absence of such lists and the 
lack of access to essential medicines are greater problems in developing 
countries than in developed ones and should be carefully taken into account when 
planning national pharmaceutical policies in such countries. The price of the 
medicines is a factor affecting the access. The WHO and HAI (Health Action 
International) have studied the access to medicines in developing countries and 
found that the affordability of medicines is poor in many countries as the prices of 
the medicines are so high that it takes several days earnings to buy one single 
COMPONENTS   OBJECTIVES 
   Access      Quality      Rational use    Drug expenditure 
 
Selection of essential drugs    x (x)    x       x 
Affordability      x         x 
Drug financing     x         x 
Supply systems     x    (x)       x 
Regulation and quality assurance  x    x       x 
Rational use        x       x 
Research      x x    x       x 
Human resources     x x    x       x 
Monitoring and evaluating     x x    x       x
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packet of medicines (Ewen and Dey 2005, Gelders et al. 2006).  The prices of 
medicines vary also between EU countries (Vogler et al. 2006). Therefore, there is 
a possibility that some medicines are bought abroad because of the lower price 
level. Government funding on medicines for the poor and disadvantaged in 
addition to the development of drug-reimbursement systems as well as supply 
and distribution systems lead to a better and more equitable access to medicines 
not only in developing countries but also in the EU.  
 
In developed countries the problems are different. There is a wide range of 
alternatives in each therapeutic group and out of each active ingredient many 
different products have been manufactured. After the brand name product launch, 
generic products, “me too” drugs and different products formulations enter the 
market (Huskamp 2006). New, more expensive classes of medicines also enter 
the market regularly, although the advantages of these more expensive medicines 
compared to the less expensive older ones are not always unquestionable 
(Huskamp 2006). An American study examined the frequency with which brand 
name vs. generic medicines were prescribed. For 20 commonly used medicines, 
the median brand-name prescription use was 98%. The researcher argued that 
physicians may find brand names easier to pronounce and remember, and 
therefore they are often used in prescriptions (Steinman et al. 2007). The problem 
of brand name use is, however, that they are more expensive than the generic 
drugs and increase the health care costs (Haas et al. 2005).  This problem also 
concerns consumers; the increasing promotion may encourage consumers to 
persist in demanding certain prescriptions from their doctor, and advertising may 
also affect patients´ OTC-medication decision-making (Deshpande et al. 2004, 
Huskamp 2006). 
 
2.3.2 Quality of medicines and minimisation of health risks 
 
Building up a national or institutional list of essential medicines that are selected 
for safety and cost-efficiency will indirectly affect the quality of medicines (WHO 
2001). However, regulation and quality assurance authorities play a major role in 
ensuring the high quality of the medicines. Counterfeit products constitute a 
quality problem for developing countries, but developed countries are not immune 
from this problem, either (e.g., it is a problem in US) (Zarocostas 2006, FDA 
2007). It has been estimated that 5-7% of all the products sold around the world 
are counterfeits (Ten Ham 2003, Deisingh 2005, WHO 2006). Counterfeits can be 
found both in brand name and generic products, and they may include products 
that 1) contain no active ingredient 2) contain the wrong quantity of active 
ingredient 3) do not contain the correct active ingredient or 4) are in incorrect or 
misleading packaging (Ten Ham 2003, FDA 2007).  The regulatory authorities 
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play a major role in the battle against counterfeits. The increasing sales of 
pharmaceuticals on the Internet may increase this problem in the future. 
 
2.3.3 Rational use of medicines  
 
Rational use of medicines can be defined in several different ways. The World 
Health Organisation defines rational use as follows:” The rational use of 
medicines requires that patient receive medications appropriate to their clinical 
needs, in doses that meet their own requirements, for an adequate period of time 
and at the lowest cost to them and their community” (WHO 2001). There are 
several factors connected to the rational use of medicines.  The essential list of 
pharmaceuticals may lead to the use of certain medicines. The regulatory 
authorities can target the issue of rational use by means of laws and regulations 
applied to different sectors connected to pharmaceuticals and their production- 
and distribution-chains (WHO 2002). The authorities´ decisions on whether 
medicines are to be sold over-the-counter or by prescription only also affect the 
use of medicines. Health care professionals (for example, physicians and 
pharmacists) have an important role in promoting the rational use of medicines. In 
addition, rational use of medicines is also dependent on whether people actually 
understand how and when their medicines should be used (WHO 2001). 
 
2.3.4 Drug expenditure 
 
The growth of pharmaceutical expenditures along with health care expenditures 
over the last 20 years is a major concern in many developed countries, especially 
in the US, but also in the European countries (Jacobzone 2000, Ess et al. 2003).  
Drug expenditures are influenced by various components of pharmaceutical policy 
(Table 1). Therefore, the impact on drug expenditures should always be 
considered by policymakers when making decisions on the different components 
of a policy. Recently, several pharmaceutical policy decisions were made in 
Europe in order to control drug expenditures (Ess et al. 2003). These decisions 
include generic systems, reimbursement policies and pricing policies. The latter 
includes product price control, reference pricing and profit controls (Jacobzone 
2000, Mrazek 2002, Ess et al. 2003, Rocchi et al. 2004, Vogel 2004, Simoens et 
al. 2005, Yfantopoulos 2008).  There have also been policies aimed at influencing 
physicians' prescribing practices (Ess et al. 2003). 
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2.3.5 Research, human resources, monitoring and evaluating 
 
Research, human resources, monitoring and evaluating are linked to all the key 
objectives of a pharmaceutical policy. Research may facilitate the implementation 
of different aspects of pharmaceutical policy, and pharmaceutical policy should be 
based on evidence that can be obtained as an outcome of research (Almarsdottir 
and Traulsen 2006).  Social pharmacy is one of the important disciplines providing 
evidence for pharmaceutical policymakers. Although there have been many 
studies inside the pharmaceutical sector focusing on practices within community 
and hospital pharmacies and the pharmaceutical industry, there is a lack of 
studies on the role of pharmaceuticals in health care and in the society (Figure 1). 
There should be more studies on pharmacoeconomics and policymaking.  
Healthcare processes, including patient and medication safety, could be studied 
from a systems approach.  This type of study could be conducted in order to 
facilitate the work of policymakers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Illustration of the function of social pharmacy research in providing 
evidence to pharmaceutical and health care policymakers and facilitating 
discourse about the role of pharmacy in health care and the society. 
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2.4 Pharmaceutical policy – A combination of different policy 
inputs 
 
Pharmaceutical policy is mainly influenced by public-health, healthcare and 
industrial policies (Traulsen and Almarsdottir 2005c).  It has also been argued that 
there are not significant differences between health care and pharmaceutical 
policies, but Traulsen and Almarsdottir (2005a) argue that different knowledge is 
required of those making pharmaceutical policy than those who make general 
healthcare policy, because of the essential differences between these sectors. 
There are differences in the actors involved, in the power relations among 
professionals and between professionals and management, as well as in the 
business and political nature of the actors involved (Traulsen and Almarsdottir 
2005a). Also, the focus of the pharmaceutical profession’s work is different from 
the focus of the professionals providing the components of health care, because 
pharmacists sell not only services but also products (Hepler and Strand 1990, 
Traulsen and Almarsdottir 2005a). Although pharmaceutical policy may be 
considered separate from health care policies, pharmaceuticals are functionally a 
part of health care. Therefore, health care and health policies should be taken into 
account when designing pharmaceutical policy. Pharmaceutical policy should be 
designed to fit within the surrounding health care system, and the goals of the 
policy should support the broader objectives created to improve health care 
(Mossialos et al. 2004).   
 
Creating pharmaceutical policy is not always simple since serving three different 
policy inputs is likely to cause conflicts between the different interest groups 
(Traulsen and Almarsdottir 2005a).  On the one hand, public health policy is 
interested in safe and high quality medicines, and on the other hand, industrial 
policies may be more interested in price development and sales promotion (Table 
2, Permanand and Altenstetter 2004). This is a fairly accurate reflection of the 
situation within the EU. Within most individual EU countries, pharmaceutical 
policies are the responsibility of the domestic Ministry of Social Affairs and Health, 
but at higher levels the EU as a whole, the situation is more complex. A central 
EU objective has been the creation of an internal market, and since 1965, of a 
pharmaceutical sector (Wahlroos 2003). When the issue concerns 
pharmaceuticals, medication safety and the promotion of public health should be 
always taken into account by all interest groups. Therefore, EU pharmaceutical 
policy has had two distinct objectives: to promote public health and to meet the 
needs of an internal market (European Commission 2000b). In the EU, matters 
related to pharmaceuticals have been characterised as matters of public health, 
but the framing of these matters has been approached with an eye towards 
industry and internal markets.  The study by Wahlroos (2003), however, 
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suggested that the EU is gradually putting more emphasis on the principles of 
safeguarding and promoting public health in its pharmaceutical policy. 
 
This contradiction between competing interests might deepen as pharmaceutical 
expenditures rise in the EU. Different EU countries have made different 
pharmaceutical policy decisions in trying to control their drug expenditures 
(Jacobzone 2000, Ess et al. 2003, Duerden et al. 2004, Rocchi et al. 2004, OECD 
2005, Espin and Rovira 2007). The different methods of cost-savings have 
affected the pharmaceutical industry, wholesalers, retailers, pharmacists as well 
as consumers and those who prescribe medicines (Ess et al. 2003). Almarsdottir 
and Traulsen (2005a) divide the cost-containment into four types: (1) price and 
profit controls in all stages of pharmaceutical distribution chains, (2) changes in 
the reimbursement system, (3) other fiscal measures and (4) quality measures. 
Italy’s pharmaceutical strategies have taken advantage of the price-related 
strategies in the battle against pharmaceutical expenditure, and in the UK, quality 
was the most influential background factor (Duerden 2004, Rocchi 2004). 
Mossialos et al. (2004) argue that the focus of the analysis should be on the drug 
consumption driven by patient need, by physicians' prescribing choices, by 
dispensing practices and by price. Although there are many possibilities for trying 
to influence costs, the policies affecting pharmaceuticals costs should be 
evaluated while incorporating of other factors such as cost efficiency, quality of 
care and equity (Mossialos et al. 2004). For example, saving money on drugs 
might sometimes lead to more hospital visits, meaning that while saving in 
pharmaceutical expenditures, other health care expenditures might increase 
(Soumerai et al. 1991). Therefore it is highly imperative to consider healthcare 
expenditures as a whole with these inter-relationships rather than as individual 
sectors alone (Mossialos et al. 2004).  
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Table 2. Competing influences on pharmaceutical policies (Source: Mossialos et 
al. 2004) 
 
Health care policy Industrial policy Public health policy 
   
• Cost containment 
and improving 
efficiency in health 
services and health 
care 
• Promoting local 
research and 
development 
capacity 
• Safe medications 
• Cost effective 
medication 
• Intellectual property 
rights protection 
• High-quality 
preparations 
• Regulating doctor 
and consumer 
behaviour vis-à-vis 
medicines 
• Supporting local 
scientific community 
• Efficacious 
treatments 
• Generic promotion 
and/or substitution 
• Generating and 
protecting 
employment 
• Innovative cures 
• Improving 
prescribing 
• Promoting small and 
medium enterprise 
policies 
• Patient access to 
medicines 
• Ensuring access to 
medicines 
• Contributing to 
positive trade 
balance 
 
 • Sustaining the 
university research 
base 
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2.5 The development of pharmaceutical policy 
 
Traulsen and Almarsdottir (2005a) argue that, while there is no single 
pharmaceutical policy, policymakers are trying to avoid formulating poor policies 
during the process. As new pharmaceutical policies are developed, there is a 
need to create new policies or modify present ones (Figure 2). The policymaking 
is often influenced by other countries´ decisions to change their policies (for 
example, deregulation in Nordic countries). However, there are many factors, 
such as social, economic, medical, health care, the political climate, as well as 
historical and institutional frameworks that affect how policies are eventually 
developed and implemented. Since directly adopting a pharmaceutical policy from 
another country does not always work, policies should be modified when applied 
to the new national contexts (Mossialos et al. 2004). New pharmaceutical policies 
are often based on older ones; the strengths and weaknesses of the older policies 
are analysed and new policies are implemented to meet the current needs. In an 
ideal case, pharmaceutical policies are based on scientific evidence, but they can 
also be based on values, ideology or politics (SIDA 2001, Traulsen and 
Almarsdottir 2005a).  The development of a policy should go through a systematic 
process, and all the parties involved, both private and public, should be consulted 
during the process (Figure 2). In Australia, this kind of process was instituted in 
order to improve the development of policies, and the quality of documents as well 
as to facilitate the implementation of the policies (NSW Health Department 1998). 
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Figure 2. Development process of pharmaceutical policy (Created based on the 
NSWs policy development guidelines, 1998) 
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2.5.1 Who is involved in pharmaceutical policymaking? 
 
The most important actors in the decision-making process involving 
pharmaceuticals and pharmaceutical policy at the level of the European Union are 
the European Commission, the European Parliament, European Council and 
EMEA (Duncan 2002, Wahlroos 2003). The responsibility of EMEA is to protect 
and promote public health, and it does not have legislative power (Garattini and 
Bertele 2004). The European Parliament and Council primarily focus on legislative 
work, whereas the European Commission is the primary organisation responsible 
for legislative work as it has the sole and exclusive right to put forth policy 
proposals, in addition to responsibility for enforcing and overseeing the 
implementation of policies. The Commission is divided into Directorate-Generals 
(DG). Issues concerning pharmaceuticals are prepared in DG Enterprise 
(European Commission 2000b).  DG Sanco is responsible for health care and 
consumer related matters (Europa 2007). Most of the health/pharmaceutical 
policy related preparation work is being done in G-Public Health, which is a 
section of DG Sanco (Wahlroos 2003). Lobbying is widely used and the 
Pharmaceutical Group of the European Union (PGEU) is an important lobbying 
organisation in the field of community pharmacies (Wahlroos 2003). National 
policies are mainly defined by the governments of the member states, the various 
national agencies of medicines, and by professional organisations.  
 
The parties included in the pharmaceutical policymaking are the pharmaceutical 
industry, healthcare professionals (such as pharmacists, physicians, nurses and 
pharmacy technicians) as well as the public (Figure 3, SIDA 2001, WHO 2001). 
The public is involved through their national parliaments, patient organisations 
and networks, even though the operation of patient organisations has been 
criticised because of connections to the pharmaceutical industry (Maynard 
2002/2003). Patient groups are often poorly funded, and therefore the industry 
uses its financial capacity to support the patient groups (Maynard 2002/2003). 
Industry has seen this as a powerful way to reinforce their influence on policy-
making (HAI 2005). The involvement of the patient groups in the pharmaceutical 
policy process has been questioned as there is some uncertainty as to whether 
the groups represent more the interests of the public or the interests of the groups' 
financial sponsors (HAI 2005). 
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Figure 3. Parties involved in pharmaceutical policy 
 
However, the majority of the public does not have advocates to represent them in 
the policy arena, even though the policies concerning pharmaceuticals – 
availability, access, pricing and safety – affect everyone’s life (Traulsen and 
Almarsdottir 2005b). The key issues of pharmaceutical policy from a public-
interest standpoint are listed in Table 3. 
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Table 3. Key issues in pharmaceutical policy from the public interest perspective 
(Source: Coulter 2002/2003) 
 
Ensuring affordable, equitable and 
timely access to effective treatments 
Access to evidence-based information 
to support informed treatment choices 
 
 
 Pricing, co-payments and 
reimbursement  
 Defining ´added therapeutic value´  
 Evaluating cost-effectiveness 
 Medicines for neglected diseases 
 
 Quality standards for patient 
information leaflets 
 Quality of information on health web 
sites 
 Tools for shared decision-making 
 Regulating advertising 
 
Clinical trials: improving recruitment, 
design and reporting by involving 
consumers 
Patient safety: reducing risk and 
monitoring adverse events 
 
 Public education about research 
methods 
 Patient involvement in trial design, 
implementation and assessment 
 Patient-assessed outcomes and 
quality-of-life 
 Research ethics and data protection 
 Publication of trials 
 
 
 Licensing and regulation 
 Drugs for children, pregnant women 
and older people 
 Packaging and labelling 
 Post-marketing surveillance 
 Safe medication practices 
 
 
2.6 Pharmaceutical policy defining the role of community 
pharmacies and pharmacist 
 
As seen in Table 3 the decisions related to pharmaceutical policy have effects on 
the lay public, their medication usage and medication safety. In most cases, 
pharmaceuticals reach the public through community pharmacies; hence, 
pharmaceutical policy also defines the role of pharmacies in society. This comes 
back to the principal question of whether pharmaceuticals are to be regarded as a 
part of health care, or as non-regulated products in conformity to the market ideal 
of business freedom? And how do these fundamental political approaches 
influence the supply of medicines? Even though the goal of policymakers is to 
ensure the overall health and well being of society, policymakers have conflicting 
views of pharmacies and pharmacists (Traulsen and Almarsdottir 2005c). 
Traulsen and Almarsdottir (2005c) argue that pharmaceutical policy depends on 
how policymakers see pharmacists and pharmacy owners in the policymaking  
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process.  The community pharmacy sector can be seen as a business 
contributing to the economic good of the community and regulated similar to other 
commercial enterprises, suggesting that the best person to own a pharmacy 
would be determined by the possession of business skills (Traulsen and 
Almarsdottir 2005c). On the other hand, community pharmacies can be seen as 
local primary health care units – as often the first contact the public has with the 
healthcare system when experiencing symptoms, and as a unit that is functionally 
integrated with other local health services (Traulsen and Almarsdottir 2005c). 
Pharmacies could be regulated as are other health care services and 
professionals, and be thus obliged to follow similar professional standards and 
evidence-based therapeutic guidelines. The final outcome of the policymaking is 
determined by the interests of policymakers: for example, is the main interest in 
EU to create a European internal market or is it more important to enhance public 
health? it is not surprising that politicians find it difficult to form a clear view of the 
role of pharmacists and pharmaceuticals when pharmacists themselves do not 
agree about whether commercial or professional values should come first (Morgall 
and Almarsdottir 1999, Traulsen and Almarsdottir 2005c). Society is lacking 
scientific evidence on the value of pharmacists’ professional contributions to 
public health.  
 
2.6.1 Deregulation of community pharmacy systems and the role of the 
pharmacy 
 
Deregulation of community pharmacy systems has been the rule in recent EU 
member states (Vogler et al. 2006). The model that has been put forth is of a 
modern system that is competitive, based on free ownership and free access to 
commodities and services, including medicines and pharmacy services. 
 
There has been debate on whether disagreements within the pharmacy 
profession have contributed to changes in professional practices and the 
regulation of the pharmacy system (Morgall and Almarsdottir 1999). In Iceland, 
the internal divergence in the profession partly contributed to the deregulation of 
the system and the break up of the monopoly in the mid-1990s (Morgall and 
Almarsdottir 1999). Other factors that contributed to these changes were the 
political desire to obtain the advantages of competition and of deregulated policy 
as well as a desire to reduce the health budget (Morgall and Almarsdottir 1999). In 
Iceland and Norway, the deregulation of pharmacy systems has dramatically 
changed the pharmacy profession. The increasing competition demands that 
pharmacists expand their knowledge of pharmaceuticals to include marketing and 
communications skills are among the most striking changes (Morgall and 
Almarsdottir 1999, Anell 2005).  Similar deregulation, although less 
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comprehensive, occurred elsewhere, e.g., in Denmark (Noerreslet et al. 2005, 
Larsen et al. 2006), but Iceland and Norway represent the extreme end of recent 
liberalisation in Europe. Through the recent deregulations, OTC medicines can be 
sold outside pharmacies (Norway, Portugal), only the maximum prices of 
pharmaceuticals are controlled and discounts, as well as the free ownership of 
pharmacies are allowed. The purpose of these changes, from the view of 
governments, has been to decrease government’s financial burden for drug 
expenditures by increasing price competition and by allowing pharmaceutical 
companies to offer discounts (Morgall and Almarsdottir 1999, Anell 2005). 
However, the deregulation strategies have brought little improvement in this 
respect  (Anell 2005). On the other hand, governments were surprised by the 
rapid changes in competitive behaviour and market structure as they had merely 
wanted to increase competition while keeping the community pharmacies and 
services otherwise unchanged. This combination of benefits was not achieved 
(Anell 2005).  
 
2.6.2 Self-medication and the role of community pharmacists    
 
The community pharmacists’ role differs between wealthy, middle-income and 
low-income countries. In the low-income and middle-income counties, pharmacies 
have traditionally been the primary points of contact with the healthcare system 
when seeking medical help. The availability of prescription medicines without 
prescription has been one factor attracting patients to pharmacies (Van der Geest 
1987, Hardon 1987, Greenhalgh 1987, Price 1989). The lack of health services 
might also force people to self-medicate. In addition, financial problems, lack of 
transportation, long waiting hours and social distance may also be factors that 
inhibit the use of health care services other than those provided by pharmacies 
(Van der Geest 1987). This is not only a problem in developing countries. In the 
US, for example, 47 million people lack health insurance and may experience 
financial barriers to accessing the health services and prescription medicines they 
need to treat their medical conditions (Department of Health and Human Services 
2007, De Navas-Walt et al. 2007). Apart from its economic importance in all kinds 
of societies, self-medication has not been recognised as an important part of 
healthcare from a health-policy viewpoint. Policy changes in the direction of 
increasing the number of non-prescription medicines and extending the range of 
existing OTCs for new indications, such as cholesterol and birth control would 
change the role of community pharmacies in developed countries as well. The 
switch from Rx to OTC medicines increases the importance of the role and 
medication counselling of pharmacists, as they might be the only healthcare 
professionals seen by people with health concerns. Pharmacists could also play a 
larger role in triage, i.e., evaluating which customers need a physician’s 
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consultation. The changes may raise the question of whether pharmacists are 
ready and qualified for this expanded role.  
 
General practitioners in particular have been worried about the increasing number 
of OTC medicines and the expanded role of pharmacists. The possibility that self-
medication is masking serious conditions and delaying diagnosis has been 
discussed (Erwin et al. 1997, Sihvo 2000). Self-medication does not necessarily 
mean that there has been contact with a pharmacist. In many Western countries 
this seldom applies as sales clerks and cashiers are taking care of OTC 
customers in pharmacies that are more like grocery stores than primary health 
care units. It seems, however, that general practitioners' attitudes have been 
changing through the years (Spencer and Edwards 1992, Erwin et al. 1996). As 
physicians have an important role in health care and they often co-operate with 
pharmacists, their attitudes have an impact on the development of health and 
pharmaceutical policies. Two comparable studies examining the views of general 
practitioners about the role of community pharmacists in dispensing over-the-
counter medications in the UK in 1990 and 1994 showed an increased 
acceptance of community pharmacists taking part in the self-medication process 
(Spencer and Edwards 1992, Erwin et al. 1996). The Finnish study of Sihvo et al. 
(1999) showed that general practitioners still viewed themselves as the most 
suitable source of drug information in many cases. Differing opinions were 
detected between general and private practitioners. Those working in the public 
health centres more often thought that pharmacists would be the most suitable 
source of medicine information. General practitioners´ more positive attitudes 
about pharmacists might arise from the fact that increased self-medication 
decreases the workload of general practitioners (Sihvo et al. 1999). The study of 
Sihvo et al. (1999) reflects the situation from the 1990s and thus does not 
necessarily reflect the current state.  The same applies to the two UK studies 
mentioned above.  
 
2.6.3 The role of community pharmacists in different countries 
 
In a Vietnamese study, consumers reported diverse views on the appropriate role 
of community pharmacists (Olsson et al. 2002). Pharmacists were seen as 
counsellors, or people to whom customers and general practitioners can turn in 
matters concerning medicines. On the other hand, pharmacists were also seen as 
the general practitioners' assistants whose role was to follow the GP’s 
instructions. The third role identified with pharmacists was as businesspersons 
who sell medicines and whose main motivation is to sell as much medicine as 
possible. Even though pharmacies and circumstances in Vietnam are different 
compared to developed countries, these results reflect the same contradictory role 
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of pharmacies, i.e., between business and healthcare, which makes it difficult for 
the public and policymakers to define pharmacists’ position in the society.  
 
In Europe, the situation is different. Pharmacies are often seen by customers as 
the best place to seek treatment for minor ailments, and as an initial step to take 
before seeking the care of a GP (Hassell et al. 1997). There is evidence that 
community pharmacists can deal with most of the minor ailments and that 
pharmacists prescribing for minor ailments would benefit patients and reduce 
costs (Bojke et al. 2004). In the UK, the pharmacists' authority to write 
supplementary prescriptions was introduced in 2003, and in 2006 the 
pharmacists’ role was expanded as they were given the right to prescribe 
independently (Tonna et al. 2007). This is the direction the Royal Pharmaceutical 
Society of Great Britain (RPSGP) would like to see the community pharmacy 
practice take in the UK, but it is not in common practice yet. Although 
prescriptions by pharmacists increased from 2,706 prescriptions in 2004 to 31,052 
prescriptions in 2006, this represented only 0.004% of all prescriptions in the 
community and primary settings in the UK (Guillaume et al. 2008). This has also 
been the case globally. Professional pharmacy organisations have created ideal 
strategies about the role of the pharmacies, but these have failed in 
implementation.  
 
In a Danish study, 12 interviews were conducted among pharmacy professionals 
and Ministry of Health representatives to define the role of pharmacist (Norgaard 
et al. 2001). Pharmacists were seen as technical advisers, drug experts, 
pharmacy leaders and providers of individual advice. As a technical adviser, the 
pharmacist is to dispense medicines and give brief instructions about the product, 
whereas a drug expert provides services and medication information to customers 
and other health care professionals. As a leader, the community pharmacist has 
responsibility for the pharmacy staff and its education. The provider of 
individualised advice has responsibility for the customer’s specific needs in order 
to determine the best medical treatment for the customers. In Denmark, 
pharmacies have been under political pressure and the role of pharmacists has 
changed in recent years (Norgaard et al. 2001). Therefore, the study by Norgaard 
et al. (2001) did not show any consistent future expectations about the role of 
community pharmacists. Pharmacists were also seen as possibly having no future 
role if their counselling becomes no longer necessary if they become simply 
become something like IT experts who offer information and sell medicines 
through the Internet, as authorities on disease management and as patient 
educators (Norgaard et al. 2001). In the US, both patients and physician 
assistants saw pharmacists primarily as a source for medications and medication 
information, but not as a contributor to comprehensive drug therapy management 
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(Bislew and Sorensen 2003). As mentioned before, the manner in which 
pharmacists are seen is a reflection of the development of pharmaceutical policy 
(Traulsen and Almarsdottir 2005c).  
 
However, the line between medicines and other goods may not always be clear 
for customers, as in some countries (the UK and the US), OTC medicines have 
been displayed in pharmacies in the manner, that they could be compared to any 
other goods. In addition, the deregulation of OTC medicines in some European 
countries has changed the role of pharmacies into something comparable to that 
of retail stores. Pharmacists may also sometimes fail to take responsibility and do 
their best in assuring that patients get the best possible outcomes from their 
medicines. Quality-of-practice evidence on this is lacking from most countries, 
including in Europe. Even in Finland, the practice is still far from optimal in many 
pharmacies, although much effort has been put into systematic service 
development with strong support from the profession and the authorities 
(Puumalainen 2005, Kansanaho 2006).  
 
2.6.4 Pharmaceutical care and the role of community pharmacists 
 
From a long-term perspective, the pharmacists’ role has shifted from 
compounding to dispensing medicines, and recently towards providing 
professional services, with this trend being driven by the concepts of 
pharmaceutical care and the clinical pharmacy (Van Mil and Schulz 2006). The 
term pharmaceutical care was published as early as 1975. Hepler and Strand 
(1990) reinvigorated the term with their 1990 definition, according to which, 
pharmaceutical care is the responsible provision of drug therapy for the purpose 
of achieving definite outcomes that improve the patient’s quality of life. Since then, 
the same term has been used for numerous different reintegrated functions (Van 
Mil et al. 2004a, Van Mil and Schulz 2006). Consequently, by the 1990s the key 
community pharmacy organisations in Europe started to look at pharmaceutical 
care as the strategic future of the profession (Van Mil and Schulz 2006). Figure 4 
describes how pharmaceutical care has been evolved from definition to 
implementation. In Finland, the study conducted by NAM in 1988 defined the lay 
public view of pharmacy services (Airaksinen 1996). The profession has had a 
proactive role in building up new professional services to meet the needs of the 
consumers and medicine users. The strategy has been successful, and 
community pharmacies have had a normative and functional role in the Finnish 
health care system, which has been recognised in recent pharmaceutical policy 
documents of the Ministry of Social Affairs and Health (2003, 2007). This has 
been the case even though Finland's neighbouring countries have been 
deregulating their systems or are debating doing so (Reje et al. 2008).    
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Figure 4. Pharmaceutical care from definition to implementation from a European 
perspective  
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2.6.5 FIP defining the role of community pharmacists 
 
The International Pharmacy Federation (FIP) is a worldwide federation of national 
pharmaceutical associations and it represents and serves pharmacy and 
pharmaceutical sciences around the world (FIP 2007a). FIP activities are 
designed to improve the long-term effectiveness of patient care. In 2000 WHO 
launched the “seven star pharmacist” concept, which introduced seven future 
roles for pharmacists, and in 2000 FIP included these roles in its policy paper 
“Good Pharmacy Education Practice” (FIP 2000). In 2006, WHO and FIP 
continued their joint project in order to further develop pharmacy practices, and 
they added one more role to the pharmacists (Wiedermayer et al. 2006). In the 
last version, pharmacists were described as 1) caregivers (provide caring 
services) 2) decision-makers (on the appropriate, efficient, safe and cost-effective 
use of resources) 3) communicators (linking prescribers and patients) 4) 
managers (managing resources) 5) life-long learners (keeping their knowledge 
and skills updated) 6) teachers (providing education and training to future 
generations) 7) leaders (able to make decisions, communicate and manage 
effectively in multidisciplinary caring situations) as well as 8) researchers (able to 
use evidence).  In the performance of these roles, pharmacists should adhere to 
the FIP code of ethics (FIP 2004). In addition, FIP has issued the Standards for 
the Quality of Pharmacy Services (FIP 1997).  
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2.7 Medication and drug safety 
 
Medication safety is an issue that has become a hot topic in the international 
medical literature (Institute of Medicine 1999, Council of Europe 2006, 2007).  It 
should always be considered when pharmaceutical policy decisions are made. As 
long as the health care system includes sufficient mechanisms to prevent 
medication errors from occurring, the safety issue will remain invisible and 
politically dormant. But should the system begin to produce errors, the issue will 
become politically heated. Little evidence exists on whether deregulation of 
pharmacy systems and of the sales of pharmaceuticals will jeopardise patient and 
medication safety. It is, however, often given less attention in pharmaceutical 
policy papers.  
 
Pharmacovigilance consists of actions taken to improve drug safety, i.e., the 
safety of the pharmaceutical products on the market  (Medicines Act 395/1987, 
WHO 2004b, STAKES and ROHTO 2006, Council of Europe 2007). Medication 
safety is related to the safety of the drug use process, including prescribing, 
dispensing, compounding, administration and information practices (National 
Coordinating Council of Medication Errors and Prevention 1998).  National 
governments and pharmaceutical policy play important roles in ensuring 
medication safety (WHO 2004b). Within the EU, there are harmonised procedures 
and regulations on the marketing authorisation required for medicinal products 
(Directive 2001/83/EC). The EMEA and national authorities are key actors, having 
responsibility for ensuring that only high quality and safe medicinal products are 
on the market. These regulations mainly impact the operations of researchers and 
the pharmaceutical industry. Drug safety is concentrated on the safety of actual 
products, their pharmacological features and effects, good manufacturing 
practices (GMP) and the availability of information on the products (Directive 
2001/83/EC, STAKES and ROHTO 2006).  Prevention and monitoring of adverse 
drug reactions is an important part of the procedure. 
 
Patient safety is defined as the freedom from accidental injuries during the course 
of medical care and encompasses activities to avoid, prevent or mitigate adverse 
outcomes resulting from health care (Council of Europe 2005). There have been 
several international efforts at improving patient safety (Council of Europe 2006). 
In 1999 the report “To Err Is Human: Building a Safer Health System” raised 
concern about patient injuries and safety, and in 2002 the World Health Assembly 
of WHO urged greater attention on patient safety, leading to the WHO's launch of 
the World Alliance for Patient Safety in 2004. In 2002, the Council of Europe's 
Committee of Experts on Management of Safety and Quality in Health Care 
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started their work on preventing adverse events in health care (Council of Europe 
2007). In 2005, the first EU conference on patient safety was held (European 
Commission 2005a). In 2005 the SIMPATIE project (Safety Improvement For 
Patients in Europe) began with the aim of creating a European-wide set of 
resources for the improvement of safety in health care. Although there have been 
several activities aiming to improve patient safety, less attention has been paid to 
safe medication practices (Council of Europe 2007). In many countries (e.g., 
Australia, Finland, USA), medication safety has been prioritised as the place to 
start in creating a systems approach to patient safety (Australian Council for 
Safety and Quality in Health Care 2002, Ministry of Social Affairs and Health 
2006, Institute of Medicine 2006).   
 
Medication safety is part of patient safety. It has been defined as freedom from 
accidental injury during the course of medication use, and includes a list of 
activities to avoid, prevent, or correct adverse drug events that may result from 
the use of medicines (Council of Europe 2005). Prevention of medication errors is 
the main idea in medication safety. All the actions that are taken or omitted by 
health care professionals (pharmacists, nurses, physicians) or by patients have an 
effect on medication safety. In 2006, the Expert Group on Safe Medication 
Practices finished their work with the publication of an international medication 
safety report with a special focus on Europe (Council of Europe 2007). The report 
mainly deals with medication errors and their prevention.  There were several 
hurdles to cross in preparing the report as European countries differ in their 
regulations, clinical practices, medication use practices and organisational 
cultures. There is also a lack of information concerning medication errors in the 
member states (Council of Europe 2007). 
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3 HEALTHCARE AND COMMUNITY PHARMACIES IN 
THE EU TREATIES AND LEGISLATION 
 
 
3.1  Healthcare in primary community legislation  
 
At the beginning of European integration, the health care sector was not 
considered a part of the integration. However, the Treaty of Rome already 
contained some indirect health considerations, such as the free movement of 
workers (patients and health professionals), the right to establishment (health 
professions and services) and the free movement of health services (Treaty 
establishing the European Economic Community 1957). The health protection 
related to pharmaceuticals was also mentioned (Treaty establishing the European 
Economic Community 1957, Cucic 2000). The Treaty of European Atomic Energy 
Community (Euroatom 1957) also deals with the health protection of the public 
and of workers (Treaty establishing the European Atomic Energy Community 
1957, Cucic 2000). In 1986, the Single European Act revises the Treaty of Rome 
and strengthens the role of the EEC in the field of health protection (Single 
European Act 1987, Cucic 2000).  
 
The Maastricht Treaty established the European Union in 1992 (Treaty on 
European Union 1992). The Maastricht Treaty defined the Community’s 
competence to act in the healthcare field. Article 3 of the Treaty deals with the 
strengthening of consumer protection, but Article 129, concerning public health, 
had the greatest influence on the healthcare sector. The key messages in this 
article were to encourage cooperation between member states to ensure a high 
level of human health, to direct actions towards the prevention of diseases, 
especially the major threats (including drug dependence) and to promote 
research, information and education on these diseases. It was also stated that 
health protection should be an essential part of the community’s other policies. 
Article 129 was followed by Article 152 in the Treaty of Amsterdam (1997). Article 
152 emphasises the Community’s role in the field of health protection, and it also 
enabled the Community to act in the new fields by assuring the quality and safety 
of organs and substances of human origin, blood and blood derivates and 
measures in the veterinary and phytosanitary fields (Treaty of Amsterdam 1997). 
Article 152 emphasises that the health care services in the community are the 
responsibility of member states.  
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Since the Treaty of Maastricht, the European Commission has started to work in 
the field of public health to prevent and control the communicable diseases in the 
Community (Decision 2119/98/EC). Since then, the public health programmes 
2003-2008 and 2008-2013 replaced the initial programmes (Decision 
1786/2002/EC and Decision 1350/2007/EC). The latest programme began in early 
January 2008, and it aims to improve citizens´ health security, promote health, 
reduce health inequalities, and generate and disseminate health information and 
knowledge (Decision 1350/2007/EC). 
 
 
3.2 Community legislation relevant to pharmaceuticals 
 
The first Community pharmaceutical directive was established in 1965 (Council 
Directive 65/65/EC). The purpose was to maintain the high level of public health 
protection by harmonising the regulations concerning marketing authorisations 
(European Commission 2000b, Wahlroos 2003). In 1975, the Committee for 
Proprietary Medicinal Products (CPMP, now Committee for Medicinal Products for 
Human Use, CMPH) and the Pharmaceutical Committee were established with 
the aim of improving access to innovative pharmaceuticals in the European 
Community (Council Directive 75/319/EEC and Council Decision 75/320/EEC). At 
the same time, the marketing authorisation procedure for mutual recognition was 
introduced. These directives were amended several times in the 1980s as the 
harmonisation in the field of marketing authorisations did not work out as planned. 
At the end of the 1980s the directive concerning pharmaceutical product pricing 
and reimbursement was introduced (Council Directive 89/105/EEC). The next 
significant step in the field of marketing authorisation harmonisation was the 
establishment of EMEA in the 1990s and the centralised marketing authorisation 
procedure (Council Regulation EEC 2309/93 replaced by regulation 726/2004, 
Wahlroos 2003). In 1992 the directive on the classification for the supply of 
medicinal products for human use was established (Council Directive 92/26/EEC). 
In the same year, the directives on the information given on medicinal products 
(regulations on PILs and labelling, Council Directive 92/27/EEC) and on the 
advertising of medicinal products (Council Directive 92/28/EEC) were established. 
Council regulation EEC/2309/93 together with the Council Directive 75/319/EEC 
requested that member states establish national pharmacovigilance systems 
(European Commission 2000b). Many of the pharmaceutical directives were 
gathered under one directive in 2001 (Directive 2001/83/EC, amended later with 
the Directives 2004/27/EC and 2004/24/EC), which included topics such as 
marketing authorisation procedures, labelling and PILs, advertising, 
pharmacovigilance, supervising and sanctions. Good manufacturing and clinical 
practices are regulated in Directive 2001/20/EC and Directive 2003/94/EC.  
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Although legislation concerning marketing authorisations is harmonised within the 
Community, the implementation of these regulations is the responsibility of 
individual member states. Even when a marketing authorisation is granted, this 
does not mean that the availability of the medicine is harmonised with other 
member states (Li Bassi et al. 2003, Ess et al. 2003). The prices and the 
reimbursement decisions are matters of the individual member states, and they 
are related to government policies, health resources and public health systems (Li 
Bassi et al. 2003). 
 
 
3.3 Community legislation, pharmacists and community 
pharmacies 
 
The directive on the recognition of professional qualifications (Directive 
2005/36/EC) came into force in 2005. The purpose of the directive is to guarantee 
that the education of professionals follows certain criteria, to facilitate the free 
movement of qualified professionals within the European Union and to facilitate 
the free provision of services.  
 
Pharmacy services are highly regulated by national agencies and other control 
bodies and member states have different legislation concerning the regulations. 
Article 152 in the EU Treaty states that a high level of human protection should be 
ensured and that the organisation of and delivery of health services to citizens are 
the responsibility of the individual member states (Treaty of Amsterdam 1997). 
Directive 2005/36/EC (amended version of Council Directive 85/432/EEC and 
Council Directive 85/433/EEC) also states that the provision of community 
pharmacy services at the national level (e.g. the geographical distribution of and 
monopoly on dispensing medicines) is the responsibility of the individual member 
states (Directive 2005/36/EC). In addition to these directives, the principle of 
subsidiary is adhered to in the Community, meaning that the Community should 
only perform those tasks that cannot be performed effectively at a national level. 
 
As the pharmaceutical policy in the EU is trying to strike a balance between two 
distinct goals – promoting public health and establishing an internal market 
(Wahlroos 2003) - there have been several cases where the European 
Commission has considered that the legislation concerning the provision of 
community pharmacy services in member states is not consistent with the EC 
Treaty, leading to proceedings against Italy, Austria and Spain (Europa 2006b). 
The Commission has taken Italy to the ECJ because of infringements concerning 
Articles 43 (Freedom of establishment) and 56 (Free movement of capital) of the 
EC Treaty (Case C-531/06, Europa 2006b). The reasoned opinion was sent to 
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Spain on account of Spain having territorial rules for the establishment of 
pharmacies and Spanish pharmacists being allowed to own only one pharmacy at 
a time. In the Austrian case, the reasoned opinion was sent because there are 
rules in Austria that restrict the free establishment of community pharmacies, e.g., 
discriminate on the basis of nationality with respect to obtaining a pharmacy 
licence and have rules limiting the number of pharmacies and the establishment 
of pharmacies to certain areas. Earlier, EJC made a decision that the Swedish 
state-owned pharmacy monopoly is in conflict with Community law (Case C-
438/02). Questions concerning online pharmacies in the Community area have 
also been resolved in the EJC (Case C-22/01). 
 
 
3.4 Community pharmacies and the internal market  
 
The European Union has had initiatives for changing member states' community 
pharmacy systems to bring them in line with the principles of the internal market. 
The idea of the internal market is to create an area without internal borders where 
people, services, goods and money may move without restrictions. The aim is to 
make the EU the most competitive and dynamic knowledge-based economy in the 
world (European Commission 2005b). Based on the state of the Internal Market 
for Services report, there were still several barriers in the way, hampering service 
development in the Community in 2002 (European Commission 2002b).  
 
The Commission announced the first draft proposal of the Services Directive in 
2004 (European Commission 2005b). The aim of the proposal was to provide a 
legal framework that would remove the barriers to the free establishment of 
service providers and the free movement of services between the member states 
(European Commission 2005b). In this proposal, community pharmacy services 
were included. If the proposal had been approved as it was, it would have been in 
conflict with the present legislation of many member states and also with Article 
152 of the EU Treaty. At the moment, pharmacy services in member states are 
strictly regulated: pharmacies are either licensed by the authorities or require 
some other registration in order to be established (Vogler et al. 2006). To put the 
directive into action, member states should have reviewed their legislation to 
eliminate any rulings that would have discriminated against foreign services 
providers (Neroth 2005). The directive would also have affected member states' 
ability to plan their health care services. Most concerns arose among the country 
of origin principle. It was argued that many safety problems would have occurred 
if services were provided in one country under the regulations of another country, 
and that service providers could have chosen countries with weakest legislation 
as their permanent base (Neroth 2005). The Pharmaceutical Group of European  
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Union, which represents community pharmacists in 29 European Countries, were 
convinced that healthcare services, including community pharmacy services, 
should have been excluded from the directive in order to guarantee sustainable, 
high quality and universally accessible health care services in Europe (PGEU 
2004). The proposal was criticised for being in contradiction to the EU Treaty and 
that it was open to interpretation (Kärkkäinen 2005). In 2005, Commissioner 
McGreevy announced that health care services would be excluded from the 
directive, but that did not mean that they would be left outside the internal market 
(Kärkkäinen 2005, McGreevy 2005). 
 
In 2006, the Services Directive (Directive 2006/123/EC) on services in the internal 
market was finally launched in order to facilitate freedom to establish distributors 
in other member states and the freedom to provide services between member 
states. Health care services were excluded from the directive. 
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4 COMMUNITY PHARMACIES IN THE EUROPEAN 
UNION 
 
 
In the EU, community pharmacies are the main distributors of medicines to 
outpatients. Yet, there is no harmonised pharmaceutical policy covering 
community pharmacy services. There are about 400,000 community pharmacies 
in Europe (PGEU 2007). The distribution of medicines is controlled through both 
supranational and national regulations (Taylor et al. 2004).  In most of the 
member states, the specific legislation governing community pharmacies is 
controlled by governments. Community pharmacies in the EU have traditionally 
been small privately owned enterprises operating under tight government controls 
(Anell 2005, Vogler et al. 2006). Although nowadays there are more similarities 
between the regulations of member states, specific national legislation on 
pharmacy services shows that large differences still remain between the 
pharmacy systems. The fundamental difference is associated with the degree of 
deregulation and ownership of the pharmacies, i.e. whether international 
pharmacy chains are allowed to incorporate in to the local markets.  
 
There are differences between nations in the requirements for becoming a 
pharmacy owner. The Swedish pharmacy system is unique: all pharmacies have 
been state owned since 1971, but the practice has been questioned in recent 
years (Westerlund and Björk 2006, Reje et al. 2008).  In some other EU countries, 
pharmacy systems have undergone changes only recently. The Norwegian 
system has changed dramatically since the implementation of its new policy in 
March 2001. Until then, each pharmacy in Norway was owned by an individual 
pharmacist. The new policy allowed free ownership and the establishment of new 
pharmacies, although pharmacists are personally responsible for the services 
provided in each pharmacy (Anell 2005). In 2006, 81% of Norwegian pharmacies 
were owned by retail chains and 19% by individual pharmacists (Vogler et al. 
2006). Sweden and Norway are the two extremes in terms of the ownership of 
community pharmacies in Europe, even though pharmacy chains similar to those 
in Norway also exist in other EU countries (e.g., in the Netherlands, the UK and 
Estonia). In most of the other EU countries, pharmacies are owned by individual 
pharmacists, although the ownership regulations also vary between these 
countries. In some EU countries, it is allowed to trade a pharmacy licence after 
owning the pharmacy for a predefined period of time (5 years in France, 3 years in 
Spain and 2 years in Portugal) (Taylor et al. 2004). The national agencies for 
medicines in Finland and Denmark select the best-qualified applicants to grant 
pharmacy licences to (Taylor et al. 2004, Vogler et al. 2006). The establishment of 
 49 
new pharmacies also differs between countries. In Germany, pharmacists are free 
to establish a new pharmacy, but in most EU countries, the establishment of 
pharmacies is regulated by demographic and geographic regulations at the 
national level (Taylor et al. 2004).  
 
Differences between member states in the pharmacies´ role as a medicine 
distributor include; the number of pharmacies per 1,000 inhabitants; the rules 
governing establishment; ownership; and the staff. Table 4 shows a comparison 
between the pharmacy systems of 12 EU countries and Norway. In some of the 
countries, for instance Denmark, Norway, the Netherlands and the United 
Kingdom, OTC medicines can also be sold outside of pharmacies (Turakka and 
Paaskoski 2005). In these countries, the assortment of non-pharmacy OTC 
medicines authorised for sale is limited.  In the Netherlands, there is a long 
tradition of drugstores (as distinct from pharmacies) being allowed to sell non-
prescription medicines, but since January 2005, OTC agents may also be sold by 
gas stations and supermarkets (Van Mill 2005).  The   deregulation  took  place  in  
Norway and Denmark in 2001.
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Table 4. PHARMACY SYSTEMS IN 12 EU COUNTRIES AND NORWAY 
Country Number of 
pharmacies 
Inhabitants per 
pharmacy 
Pharmacists per 
pharmacy 
Medicines sales 
outside 
pharmacies 
Establishment of 
pharmacies 
 Pharmacy 
ownership 
Pharmacy chains 
allowed 
 
Norway 
 
559 
 
8,533 
 
1.8 
 
Yes 
 
FREE 
 
Legal entities* 
 
Yes 
 
Sweden 
 
900 
 
10,000 
 
0-2 
 
No** 
 
N/A 
 
State 
Aboteket AB owns 
all pharmacies 
 
Finland 
 
802 
 
6,580 
 
1.7 
 
No** 
 
Licence 
 
Pharmacist 
 
No*** 
 
Germany 
 
21,392 
 
3,900 Not available 
 
Yes 
 
Free 
 
Pharmacists 
 
No*** 
 
Netherlands 
 
1,825 
 
8,300 
 
1.6 
 
Yes 
 
No licence 
 
Anyone 
 
Yes 
 
Spain 
 
20,741 
 
2,156 
 
2 
 
No 
 
Licence 
 
Pharmacist 
 
No 
 
Ireland 
 
1,394 
 
3,038 
 
1.4 
 
Yes 
 
Free 
 
Anyone 
 
Yes 
 
Austria 
 
1,200 
 
6,729 
 
4 
 
NO 
 
Licence 
 
Pharmacist 
 
No 
 
Denmark 
 
322 
 
16,916 
 
2.6 
 
Yes Licence Pharmacist 
Maximum 4 
pharmacies 
 
France 
 
23,228 
 
2,696 
 
2.4 
 
No Licence Pharmacists No 
 
Italy 
 
18,000 
 
3,220 
 
2.77 Yes (only NPMs) 
 
Licence 
Pharmacists 
(wholesalers ****) 
Yes, but only public 
pharmacies 
 
Portugal 
 
2,775 
 
3,782 
 
2.1 Yes (only NPMs) Licence 
Anyone, with 
some exceptions* 
No, Maximum 4 
pharmacies 
 
UK 
 
12,943 
 
4,900 Not available 
 
Yes 
Dispensing 
contract 
 
Anyone 
 
Yes 
 
*Not pharmaceutical manufacturers or prescribers  ** In sparsely populated areas pharmacy representatives and outlets allowed.  
In Finland NRT products have been available in supermarkets and other retails outlets since 2006. 
*** 1 main pharmacy and max. 3 branch pharmacies /owner. **** Wholesalers can own public pharmacies. 
NPM = non-prescription medicine. 
Source: All data come from PGEU and were updated in 2006.
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Pharmacists by law must have similar educational backgrounds irrespective of the 
member state in which they work, although the way the curriculum is designed in 
different pharmacy schools and member countries differs markedly. According to 
Directive 2005/36/EC, pharmacists must have a formal university degree.  The 
competencies of other pharmacy workers and the work that they are allowed to do 
in the community pharmacy differ between the nations (Table 5, Vogler et al. 
2006). Worldwide, pharmaceutical education has shifted towards including more 
clinical content, and pharmaceutical care, including patient interactions, have 
become part of the pharmacy curriculum and continuing education programmes of 
many countries. 
 
 
 
 
Table 5. Pharmacy education in different EU countries and Norway 
 
 
 
Country 
 
Education of those who are authorised to dispense 
medicines  
 
Finland 
Pharmacist:  a 5-6 year university degree (M.Sc. in Pharm.) 
Prescriptionist:  a 3-year university degree (B.Sc. in Pharm.) 
 
Spain 
Pharmacist:  a 5-year university degree 
 
 
Norway 
Pharmacist : a 5-year university degree 
Prescriptionist: a 3-year university degree 
 
Germany 
Pharmacist: a 5-year university degree 
 
The 
Netherlands 
Pharmacist : a 6-year university degree 
Pharmacy assistant: a 4-year secondary education 
 
Sweden 
Pharmacist: a 5-year university degree 
Prescriptionist: a 3-year university degree 
 
Ireland 
Pharmacist: a 5-year university degree 
Qualified assistant or assistant to pharm. Chemist: a 3-years 
vocational training 
 
Austria 
Pharmacist: a 5.5-year university education 
Pharmacy assistant: a 2 or 3-years vocational training 
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4.1 Pharmacy services and pharmaceutical care in European 
community pharmacies  
 
Community pharmacies in the EU offer a wide range of professional and 
commercial services to their customers. Since the philosophy of pharmaceutical 
care was internationally launched in 1990 (Hepler and Strand 1990), community 
pharmacists have been pushed by their professional organisations to take more 
responsibility for patient care (FIP 1997). As a consequence, some pharmacists 
have developed their services and taken a more comprehensive role as health 
care professionals (Farris et al. 2005, Van Mil and Schulz 2006). However, the 
change from traditional dispensing to cognitive services has been slow, and the 
pharmacies are dividing into two camps in this respect, even within the same 
country: those which are integrating health care services by providing a variety of 
professional services, and those that limit themselves to traditional dispensing 
(Kansanaho 2006). Countries where dispensing medicines is no longer 
pharmacies’ sole function have demonstrated how the role of pharmacists can be 
expanded. Within the EU, those countries particularly include the UK, the 
Netherlands, Sweden, Denmark and Finland, though most European countries 
have conducted at least some local service development projects. International 
professional organisations, such as FIP, WHO EuroPharm Forum, and 
Pharmaceutical Care Network of Europe (PCNE) have had a crucial role in 
providing platforms for sharing experiences of service development projects in 
different countries and extending knowledge about their implementation and 
evaluation.    
 
Regarding professional community pharmacy services, the minimum that is 
required by law in most EU countries is that people can obtain health advice and 
assistance with pharmacotherapeutic issues for managing their diseases 
(Roughead et al. 2005, Farris et al. 2005, Puumalainen 2005, Van Mil 2005, 
Eickhoff and Schulz 2006, Kansanaho 2006, Westerlund and Björk 2006, Bell et 
al. 2007). There is also evidence of the development of more advanced medicine-
related services, one of the most popular being different kinds of medication 
review services carried out in collaboration with physicians (Royal et al. 2006, 
Holland et al. 2008). The most recent discussion has revolved around 
pharmacist’s involvement in prescribing (Tonna et al. 2007, Guillaume et al. 
2008).  
 
One of the most studied areas in professional community pharmacy services is 
medication counselling practices, which has been under discussion since the 
1980s (Airaksinen 1996, De Young 1996, Vainio 2004, Puumalainen 2005, 
Kansanaho 2006).  This is also a service area prioritised by consumers 
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(Airaksinen 1996). Most of the research and development has focused on 
communications practices regarding prescription medicines, the lack of attention 
paid to the role of self-care and self-medication as the means by which many 
people manage their symptoms  (Sihvo 2000, Turunen 2007).  This trend can also 
be seen in health policy decision-making, which has not taken a full advantage of 
the fact that, as the number of OTCs and the variety of symptoms that can be 
managed by OTCs has increased, the importance of providing counselling on the 
proper use of OTCs has increased. On the contrary, many countries have made, 
or are in the process of making, political decisions for releasing OTC medicines to 
the open market. This trend has been particularly pushed by the lobbying 
organisations of the retail market. The drug industry has discrete opinions, part of 
the companies promote the free market and use consulting firms to assemble 
evidence in support of their agendas (Shifman and Sweeney 2007).  
 
Although it is common for pharmacies to have a self-selection department, it is not 
so common for them to have OTC medicines available there (i.e., self-medication 
products that have a marketing authorisation as medicinal products). The OTC 
assortment available in the self-selection area may be limited, or contain only 
other health-related goods, such as health food products, hygiene and health 
supplies. A system with consumers’ free access to all OTC medicines is most 
typical in countries with an Anglo-Saxon business orientation. Regardless of the 
way of organising OTC sales in the pharmacy, it can be done so that pharmacists 
are available for counselling. In Finland, for example, medication counselling on 
OTC medicines is required by law, even though all the OTC medicines are 
available to the public in the self-selection department (Medicines Act 395/1987).  
The counselling service is provided free of charge. Thus, pharmacists are 
providing a potential professional primary-health-care resource in managing minor 
symptoms, although evidence is lacking on its health-economic value and it has 
not been included in health and pharmaceutical policy decisions.   
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4.1.1 Initiatives taken to improve professional community pharmacy practises 
 
The trend is that initiatives taken to improve professional community services are 
mainly taken voluntarily within the profession and without incentives for providing 
the new services.  
 
In Finland the patient counselling development project TIPPA (2000-2003) 
promoted long-term professional development in community pharmacies 
(Puumalainen 2005, Kansanaho 2006). TIPPA was a systematic project 
implemented in Finnish pharmacies nationwide. TIPPA project was supported by 
the Ministry of Social Affairs and Health, the National Agency for Medicines and 
the Social Insurance Institution, and these authorities were also actively involved 
in planning the project and following up on its progress. An important part of the 
TIPPA project was a drug information database (Tietotippa) created to support 
pharmacies in their daily work. In addition, emphasis was put on determining how 
training and extension studies could be directed to support the development of the 
skills needed in professional community pharmacy services (e.g., management 
skills). 
 
Another area of discourse based on the pharmaceutical care philosophy by 
Hepler and Strand (1990), is related to the recognition of drug-related problems 
(DRP) in pharmacies. For this purpose, a DRP classification model has been 
developed (Westerlund 2002, van Mil 2005, PCNE 2006). A huge effort has been 
made to create computer-based programs to identify DRPs, and in many 
countries, DRP identification, resolution and documentation have been at the core 
of pharmaceutical care (Van Mil et al. 2004b). In Sweden the DRP classification 
system was incorporated into the Swedish community pharmacy software in 2001 
(Westerlund 2002). During the first year, nearly 300,000 prescription and OTC-
related DRPs showed that adverse reactions were the most frequently 
documented type of drug-related problem (Westerlund and Björk 2006). In the 
Netherlands, the following DRPs are being monitored by all three competing 
pharmacy software products: daily dose, interactions, double medication, 
contraindications, allergies and adherence (Van Mil 2005). The pharmacists 
resolve the detected problems together with the patient and/or the physician.  
 
Pharmacists are also urged to provide preventive care services to patients 
suffering from chronic disease (EuroPharm Forum 2008a).  In Germany, an 
asthma programme was started to change the image of community pharmacists 
as being merely a dispenser of medicines to that of a highly qualified advisor. The 
asthma programme started initially as a controlled intervention trial, leading to an 
intervention study and later, in 2003, to nationwide implementation (Eickhoff and 
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Schulz 2006). This project demonstrated that community-pharmacy based 
interventions significantly improved clinical parameters, asthma-specific quality of 
life, self-efficacy, self-management and the self-knowledge of the patient (Eickhoff 
and Schulz 2006). Since the asthma program was introduced, similar methods 
have been offered for different diseases, such as chronic pulmonary disease, 
coronary heart disease/angina, diabetes and breast cancer.   
 
In recent years, there have been multiple nation-wide projects in Finnish 
pharmacies in order to prevent, or to enhance the treatment of, national diseases. 
These programmes have been part of the national health programmes, and the 
majority of Finnish pharmacies have participated in the programmes. The primary 
purpose of the professional programmes has been to ensure the success of the 
treatment of patients in an optimal way. A substantial part of the work towards 
reaching the target involves co-operation between the different healthcare 
professionals and pharmacies.  The first programme, the Asthma Programme, 
started in pharmacies in 1997 following the Diabetes Programme in 2001 and 
Heart Disease Programme in 2005 (The Association of Finnish Pharmacies 
2005). The Association of Finnish pharmacies (AFP) evaluates the 
implementation of these programmes and organises training that supports the 
pharmacies involved in the programmes. AFP is also regularly in contact with the 
national programme-coordinators.  
 
4.1.2 Services provided by community pharmacies in Europe 
 
Blood pressure and glucose and cholesterol level measurements are everyday 
pharmacy practise in many countries, although the motives of pharmacy owners 
for providing these services are discrete. They can be planned as follow-up 
activities to assure optimum outcomes of drug therapies when they support health 
strategies and health policy goals.  On the other hand, they can be provided as 
sales promotion activities of the pharmacy without an evidence-base and without 
integration with other local health services. When properly planned and integrated 
into the healthcare system, these services can help people to maintain health and 
keep them aware of the effects of their medicines (Gastelurrutia et al. 2005, 
Westerlund and Björk 2006). There is also evidence that people are willing to use 
these services if provided by pharmacists (Nuffield Foundation 1986, Airaksinen 
1996, Närhi 2001).   
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Information is accumulating on the wide range of other services provided by 
community pharmacies in various European countries either on the routine or 
experimental basis. These include many kinds of health promotion services, and 
in the case of illnesses, the promotion of rational prescribing and the appropriate 
use of medicines (Eickhoff and Schulz 2006). In Sweden, pharmacists offer 
fitness check services, providing advice on weight loss, diet and health, as well as 
lectures on fitness, health and group exercises (Westerlund and Björk 2006).  
Smoking cessation services are offered by pharmacists in many countries, 
including Finland (Gastelurrutia et al. 2005, Westerlund and Björk 2006, Eickhoff 
and Schulz 2006, The Association of Finnish Pharmacies 2006a, Herborg et al. 
2007).  In many countries (e.g., the UK, Spain, Portugal) community pharmacists 
are involved in providing methadone-supply services to opiate-addicted patients 
(Gastelurrutia et al. 2005, Costa et al. 2006, Noyce 2007). Moreover, a needle 
exchange programme is used in many EU countries (Gastelurrutia et al. 2005, 
EMCDDA 2005).   
 
Although community pharmacists in the EU are involved in offering a wide range 
of services within primary health care, there is no harmonised policy on the 
services that pharmacists should or must offer. Many of the pharmacy services 
are offered free of charge, but the trend seems to be that additional services are 
becoming chargeable. In many countries, new services have become 
reimbursable, so that health systems and insurance companies are paying for 
these services. For example, in Germany a pharmacy-based intervention service 
for asthma patients was proven effective and therefore the health insurance fund 
made a contract with the representatives of community pharmacists in order to 
take part in this programme (Eickhoff and Schulz 2006). In Portugal, community 
pharmacists have obtained reimbursement for diabetes disease management 
(Anderson 2005, Farris et al. 2005).  This service is a combination between 
disease state management principles and a pharmaceutical care approach. The 
certified pharmacists analyse patient complaints, measure blood glucose against 
target values and review drug therapy between physician visits (Anderson 2005). 
In many countries, pharmacies offer medication review services (Westerlund and 
Björk 2006, Herborg et al. 2007, Noyce 2007). In Finland, automated dose 
dispensing for the elderly, including medication review, is the first service 
mentioned in the Health Insurance Act that is reimbursed by the public insurance, 
which covers the whole population (Health Insurance Act 1224/2004). 
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4.2 A comparison of Spanish and Finnish community pharmacy 
systems and practices 
 
In both Spain and Finland, medicines can be legally sold only in pharmacies. 
Spain differs from Finland in that there is more competition among pharmacies 
since there are more pharmacies per inhabitant (1:2000 in Spain vs. 1:6500 in 
Finland) (WHO 2000, Gastelurrutia et al. 2005, The Association of Finnish 
Pharmacies 2007a). However, in Spain there are on average fewer pharmacists 
or academic prescriptionists (who are allowed to dispense medications) per 
pharmacy outlet – two in Spain compared to 6.3 in Finland  (Vogler et al. 2006, 
The Association of Finnish Pharmacies 2007b). The size of pharmacies in terms 
of number of personnel and operations performed is also smaller in Spain than in 
Finland on average. In Spain there are on average 3.3 persons and in Finland 
more than 10 persons who work in the pharmacy (Vogler et al. 2006, The 
Association of Finnish Pharmacies 2006a). In both countries, pharmacies are 
equipped with premises for preparing medicines extemporaneously, and the main 
operations are mostly computerised (Finland 100% vs. Spain 96%). In Finland, e-
prescribing has been under development since the end of the 1980s (Hyyppönen 
2005). Electronic prescribing has been piloted nationwide since 2002, and the law 
on e-prescribing was enacted in 2007 (Hyyppönen 2005, Law on Electronic 
Prescription 61/2007).  It has been predicted that by 2010 half of all prescriptions 
in Finland will be e-prescribed (Vogler et al. 2006, Ministry of Social Affairs and 
Health 2008).  
 
 Pharmacies in both Spain and Finland are privately owned, and only pharmacists 
are allowed to own a community pharmacy, with two exceptions. In Finland there 
are two University pharmacies, one owned by Helsinki University and another by 
Kuopio University, both having a special duty by law to support pharmacy 
education and research (Medicines Act 395/1987). In Finland pharmacists are 
able to operate a maximum of four outlets: one main pharmacy and, with 
approval, up to three branch pharmacies. In Spain one pharmacist can own only 
one pharmacy, but multiple pharmacists can also own one pharmacy. However, 
pharmacy chains are not allowed forms of ownership in either country, though 
private community pharmacies have formed coalitions for coordinating marketing 
services and staff training in Finland.  In Spain a new pharmacy can be 
established or a licence for an existing pharmacy can be bought if the current 
licence has operated the pharmacy for at least 3 years. The rules for establishing 
a new pharmacy are based on the population per pharmacy and the proposed 
distance to the closest neighbouring pharmacies (Gastelurrutia et al. 2005). The 
minimum population required to open a new pharmacy ranges from 700–2,500 in 
different provinces and the minimum distance between pharmacies ranges from 
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150 to 250 meters. In Finland, a licence from the National Agency for Medicines is 
needed to operate a retail pharmacy in a specific municipality or part of it. If there 
are several applicants for a pharmacy licence, it shall be granted to the applicant 
whom the NAM considers best qualified to operate the pharmacy (National 
Agency for Medicines 2007). Applicants’ qualifications are assessed by 
considering their demonstrated competence, by their aptitude for business as 
shown in their earlier work in pharmacies, and by other work relating to 
pharmaceutical services (Vogler et al. 2006, National Agency for Medicines 2007).  
Recently, more emphasis has been put on the managerial skills of the applicants. 
 
In both countries, only academically trained pharmacy workers are allowed to 
dispense medicines and counsel patients. In Finland there are two university 
degrees for pharmacy: Master of Science (Pharm.) and Bachelor of Science 
(Pharm.). The Master of Science degree takes five to six years to complete, 
including six months of practical training in a community or a hospital pharmacy. 
The Master of Science degree is granted by either Helsinki or Kuopio University. 
The Bachelor of Science degree takes 3 years to complete, including a similar 
practical training of six months. The Bachelor's degree can be obtained from 
Helsinki or Kuopio University or from Åbo Academi. Only those having a Master of 
Science (Pharm.) degree can be granted a pharmacy licence, which expires when 
they reach 68 years of age (Medicines Act 395/1987). In Spain, there are 14 
pharmacy faculties where individuals can study for a higher university degree in 
pharmacy (FIP 2007b, Mason 1999, Vogler et al. 2006).  The program takes five 
years to complete and is followed by six months of supervised work in a 
community or hospital pharmacy. After qualifying, the pharmacist can work 
anywhere in Spain. Hospital pharmacists, however, undergo several more years 
training before they can be in charge of a pharmacy. In both countries, continuing 
education is mandated by law and strongly supported by the professional 
associations, in Finland by the Association of Finnish Pharmacies and the 
Medicines Act 395/1987) and in Spain by the general Spanish Council of 
Pharmacists (Vogler et al. 2006) and the law on health professions (44/2003). 
 
In both countries there is a regulated monopoly that emphasises professional 
practice and service obligations without price competition (Gastelurrutia et al. 
2005, Bell et al. 2007). In both countries the government fixes the pharmacy profit 
margins, and the availability of generic substitution is obligatory by law. In Spain a 
reference price system is in use (Montoro 2000).  In Spain there are more 
pharmaceuticals registered on the market than in Finland (11,783 in Spain vs. 
6,078 in Finland in 2005, including different pharmaceutical forms and strengths), 
but the number has been steadily increasing in Finland since generic substitution 
was implemented in 2003 (Vogler et al. 2006). In Spain there is also a wide range 
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of non-pharmaceutical products available in pharmacies (Vogler et al. 2006). In 
Finland, 95% of pharmacy sales are drugs vs. 85% in Spain (Gastelurrutia et al. 
2005, The Association of Finnish Pharmacies 2007b). Furthermore, there are 
more self-care alternatives in Spanish than in Finnish pharmacies, because some 
prescription medicines, such as antibiotics, may be purchased directly from the 
pharmacy without a prescription (Mason 1999, Figueiras et al. 2000, Caamano 
Isorna et al. 2004, Ras Vidal and Moya Ortiz 2005, Barbero-Gonzalez et al. 2006). 
However, recently authorities have begun to enforce the regulations governing 
prescription-only medications (Jubete Vazquez 2004, Scrip 2005). 
 
 In Spain, medicine prices are lower than in Finland, but when adjusting for 
purchasing power, the difference is not remarkable (Vogler et al. 2006). In both 
countries, the price of prescription medicines has dropped in recent years (Vogler 
et al. 2006).   However, when examining the reimbursement systems of the two 
countries, the medicine expenses paid by the consumers differ greatly, especially 
for pensioners. In Spain, the reimbursement system provides medicines to 
pensioners for free; working age people pay 40% and those suffering from chronic 
illnesses 10% of the cost of their medicines. In Finland, the reimbursement rate is 
determined by the disease, being classified into three categories according to the 
severity of the disease.  Drugs for the treatment of life threatening and severe 
conditions, such as cancer and diabetes, are 100% reimbursed with a €3 
deductible per medicament.  Drugs for chronic conditions such as hypertension, 
asthma, dyslipidemia and cardiac insufficiency are included in the category with 
72% reimbursement.  Any other drugs that have an approval from the 
government-based Pharmaceutical Pricing Board to be reimbursed because of 
having a reasonable wholesale price are reimbursed in the Basic Refund 
Category, which is 42% of the retail price (The Social Insurance Institution 2006, 
Health Insurance Act 1224/2004). In Spain approximately 25% and in Finland 
16% of total healthcare expenditures are for drugs (Gastelurrutia et al. 2005, The 
Association of Finnish Pharmacies 2007b). 
 
Spanish and Finnish pharmacies offer a wide range of services to their customers. 
Medication counselling is the most important service pharmacies routinely offer. In 
both countries, the development of professional services has been strongly 
influenced by the WHO Euro Pharm Forum, in which they have been actively 
involved since the establishment of the Forum in 1992 (EuroPharm Forum 
2008b). Both countries were among the first countries to carry out the “Ask About 
Your Medicines" campaign starting in 1993 (Airaksinen 1996, Airaksinen et al. 
1998). Since then, medication counselling has had a special emphasis in the 
development of community pharmacy services in Finland, as can be seen in, e.g., 
the strategies of the AFP (The Association of Finnish Pharmacies 1997, 1998, 
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1999). To follow-up the development of medication counselling practices in 
Finnish community pharmacies, AFP conducted a pseudo customer study in 
1998, among one of the first countries using the method in community pharmacy 
context. The study revealed a need for further development, and led to the launch 
of the four-year TIPPA project in 2000 to improve the medication counselling of 
community pharmacies (Puumalainen 2005, Kansanaho 2006). In connection with 
this project, medication counselling has been widely studied, also from an 
organisational perspective, and improvements in practices have been 
documented  (Puumalainen 2005, Kansanaho 2006).   
 
In both countries, pharmacists are increasingly involved in health promotion and in 
the follow-up of patients with chronic conditions. In Spain, in contrast to Finland, 
measurement and laboratory tests, such as weight, height, blood pressure 
measurements and biochemical blood tests (glucose and cholesterol levels) are 
taken by pharmacists (Gastelurrutia et al. 2005). Finnish authorities allow 
pharmacists to be involved in screening only to a limited extent to ensure that 
practices remain evidence-based and that services remain integrated with local 
health services  (Vogler et al. 2006).  
 
In Finland, pharmacy programmes are designed to be integrated with national 
health promotion programmes.  Over the years, pharmacists have been involved 
in asthma, diabetes, heart and hypertension, and obesity and smoking cessation 
campaigns (Mason 2000, Haahtela et al. 2006, Bell et al. 2007). The national 
Asthma Programme started in Finnish pharmacies in 1997, and now almost all of 
the Finnish pharmacies have taken part in this program (Haahtela et al. 2006). 
The aim of this project is to improve asthma care in co-operation with the local 
healthcare centres. In each pharmacy, one pharmacist is nominated to specialise 
in asthma and its treatment and to become a contact person.  Similar 
programmes have been launched in diabetes and in heart diseases. The 
operative of the diabetes programme has been in the prevention of type 2 
diabetes and in treatment effectiveness.  Four-fifths of the Finnish pharmacy 
outlets have contact persons in diabetes programs and 66% of the pharmacy 
outlets have a heart programme contact person (The Association of Finnish 
pharmacies 2007b). In Spain, professional campaigns have been implemented in 
AIDS, hypertension, menopause and anorexia nervosa (Mason 1999). Since 
nicotine products became available in supermarkets and other retail outlets in 
Finland in 2006, pharmacies have launched a new type of cessation programme 
for smokers. The price of this service includes an independent pharmacist’s 
counselling to guide the patient in their project. The pharmacists and patient meet 
4-5 times during a span of 3-6 months (The Association of Finnish Pharmacies 
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2006b). In Spain as well, smoking cessation activities are offered (Gastelurrutia et 
al. 2005).  
 
In Spain, some pharmacies offer and are paid for methadone administration 
services to patients on opiate withdrawal programmes (Gastelurrutia et al. 2005).  
In Finland, the Pharmacy Agreement Model is in use with patients who have an 
addiction to medicines or drugs. It may be also used to prevent addiction or to 
assist patients whose medicine supply should be limited for some other reasons 
(Holopainen et al. 2005). In this model, physician and patient sign an agreement 
that patient may only receives a certain amount of medicines from the pharmacy 
at a time. The patient is obligated to always use the same pharmacy and to fetch 
the medicines by himself/herself. Pharmacies have an important role in this co-
operation (Holopainen et al. 2005). 
 
In Finland automatic dose dispensing (ADD) has been launched in community 
pharmacies. In ADD, patients’ medicines are packed in single dose packages for 
two weeks by the automatic tablet-packing machine. The aim of this service is to 
increase medication safety, decrease drug costs and reduce the workload of 
pharmacists or other health care professionals work involved in manual dosage 
dispensing (Saikkonen 2003). By the end of 2005, 10% of Finnish pharmacies 
were equipped to offer automated dose-dispensing, and in the beginning of 2008, 
more than half of the pharmacy outlets were offering this service (The Association 
of Finnish pharmacies 2006a, 2008). The Finnish Social Insurance Institution was 
involved in this process, so that these services are reimbursed for patients over 
75-years who are on multiple medications. Patient medicines should be reviewed 
before this service is implemented (Health Insurance Act 1224/2004, The Social 
Insurance Institution 2006).  
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5 SELF-MEDICATION IN THE EUROPEAN UNION 
 
 
Council Directive 92/26 Article 3: “Medicinal products shall be subjected to 
medical prescription where they are likely to present danger either directly or 
indirectly, even when used correctly if utilised without medical supervision. They 
are frequently and to a very wide extent used incorrectly, and as a result are likely 
to present a direct or indirect danger to human health, or contain substances or 
preparations thereof the activity and/or side effects of which require further 
investigation, or are normally prescribed by a doctor to be administered 
parenterally”. 
 
EU has directives on which medicines should be available over-the-counter and 
which by prescription (Council Directive 92/26/EEC and Directive 2001/83/EC), 
but the final decision as to whether a medicinal product is subject to medical 
prescription or not is taken in EU countries by national authorities connected to 
the ministries of health. Even though EU countries have approved the same 
directive, there are still differences in the classification of certain OTC products 
(Table 6). There are also differences between countries in the places where non-
prescription medicines may be sold (see Table 5). 
 
 
Table 6. Legal classification status of selected ingredients in the EU 
 
Active ingredients          EU-NATIONS 
  Austria Denmark Finland France Germany Spain Sweden UK 
Glucosamine OTC OTC Rx - OTC Rx 2004* OTC 
Naproxen 2000* Rx Rx 2007* 2001* 1996* Rx Rx 
Cetirizine 2001* 1985* 1994* 1998* 1995* 2002* 1999* 1993* 
Omeprazole Rx Rx Rx Rx Rx Rx 1999* 2004* 
Ranitidine OTC 1989* 1996* 1997* 1999* 1998* 1995* 1994* 
Simvastatin Rx Rx Rx Rx Rx Rx Rx 2004* 
Levonorgestrel Rx Rx 2002* 1999* Rx Rx 2001* 2001* 
Tetracycline Rx Rx Rx Rx Rx Rx Rx Rx 
 
Rx, prescription only, OTC, over the counter, -, non-authorized or non-marketed. 
OTC use may be restricted to some specific dosages or routes to administration 
Source: AESGP 2007.  
*Year when the product became available over the counter. 
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 In recent years several prescription products have become available without 
prescription. Some of these RX-to-OTC switches have divided opinions and 
created quite a lot of discussion regarding safety matters (such as adverse 
reactions, misdiagnosis, misuse, delays in primary diagnosis and drug-to-drug 
interactions), costs, advertising, availability and access (Bradley and Bond 1995, 
Bradley and Blenkinsopp 1996, Byrns 1998, Soller 1998, Lipsky and Waters 1999, 
Aronson 2004, Fenichel 2004, Shiffman and Sweeney 2008, Table 7). 
 
 
Table 7. Positive and negative aspects of Rx-to-OTC switches 
 
 
 
Levonorgestrel, an emergency hormonal contraception, has been one of the 
medical treatments raising discussion. In many EU-countries (e.g., Belgium, 
Finland, France, Sweden and UK) these emergency contraceptive pills have been 
switched from Rx to OTC products (AESPG 2007). Several possible risks were 
recognised, but the change was supported because it was predicted to reduce 
unintended pregnancies and abortions as well as healthcare costs (Camp et al. 
2003). Reducing third party healthcare costs has been behind many of these 
switches. An American study suggested that Rx-to-OTC switches may decrease 
the utilisation and cost of all prescription drugs and combinations in the group 
studied (Sullivan et al. 2005).  There has been some debate whether these 
switches are made with intentions to switch costs from insurance companies to 
patients: in many countries national or private insurance companies do not cover 
OTC medicines (Bradley  and Blenkinsopp 1996). However, shifting costs is not 
the only factor driving these switches. Nowadays, people are more educated and 
more interested in self-care. The responsibility for health care is shifted to 
consumers, and an extensive information network could make people more 
+ Positive aspects - Negative aspects 
 
 Easy access 
 Rapid access 
 Independency 
 Decrease in utilisation of Rx-
medicines 
 Costs shifted from health care 
system to patients 
 Reduces amount of contacts with 
GPs 
 
 
 Possibility of ADR´s will increase 
 Possible interactions with other 
OTC- or RX-medicines 
 Use might mask symptoms of 
serious illnesses 
 Possibility of choosing wrong 
medicines/making wrong 
diagnoses   
 Incorrect use 
 Misuse/abuse 
 Change in the status of 
medicines  
 Increases indirect healthcare 
costs if health problems first 
mistreated by OTC medicines    
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informed and perhaps more willing to make their own decisions (Byrns 1998, Juhl 
1998). OTC status would enable easier and more rapid access to these 
medicines, as well as more independence in choosing medicines for patients who 
can afford them.  
 
On the other hand, problems might occur due to self-medication. Non-prescription 
medications have the potential for misuse. Previous studies revealed that the 
misuse of particular medicines (for example painkillers, cough mixtures, sleep 
aids, laxatives and antihistamines) is widespread, and well known to pharmacists 
(Hughes et al. 1999, Wazaify et al. 2005, Steinman 2006).  An Irish study 
concluded that one-third of the public had personally encountered misuse or 
abuse of OTC medicines (Wazaify et al. 2005). In an American study more than 
one-third of patients indicated that they exceed the recommended dose of their 
OTC medicine to get the desired effect from the product (Schulke 1998). One 
study in Iceland suggested that liberalising the drug distribution system could be 
one factor leading to the increase in misuse of non-prescription analgesics 
containing codeine (Almarsdottir and Grimsson 2000). As the status of medicines 
has been changed from Rx –to OTC, the responsibility for screening misuse has 
shifted from general practitioners to pharmacists. A Swedish study demonstrated 
the need for more professional attention and intervention by pharmacy staff to 
prevent drug-related problems in non-prescription customers (Westerlund et al. 
2001). Pharmacists have a major role in assuring that patients know how to use 
their medicines and that they understand the possible side-effects. A Welsh study 
reported that, on average, only one out of five users of ibuprofen could name one 
of its side effects, even though ibuprofen is one of the most common products to 
cause serious side-effects (Hughes et al. 2002). 
 
The issue remains unresolved of who will take care of the medication-related 
problems of the public if more and more medicines are released outside the 
control of either physicians or pharmacists.   
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5.1 Undesirable self-medication 
 
Some EU countries have faced problems where prescription medicines have been 
sold and used as non-prescription medicines. As antibiotic resistance is a rapidly 
increasing global problem, antibiotic use as a self-medication has been studied in 
different countries. A broad, European antibiotic-usage study examined self-
medication with antibiotics in 19 European countries (Grigoryan et al. 2006). Clear 
differences were found between countries: self-medication rates were high both in 
Eastern and Southern European countries and low in Northern and Western 
Europe.  Younger age, higher education and the presence of a chronic disease 
were associated with greater use. A Spanish study suggested that 50% of 
Spanish families used antibiotics as self-medication (Ras Vidal and Moya Ortiz 
2005). A Swedish study suggested that 4% of Swedish respondents had 
antibiotics at home, but they were in almost all cases obtained with a prescription 
(Svensson et al. 2004). A Danish study suggested that 97% of antibiotics had 
been obtained after a medical consultation (Muscat et al. 2006). In a Maltese 
study 19% of the respondents admitted taking antibiotics without a prescription, 
and in Poland 13% of antibiotic therapies were taken without medical supervision 
(Borg and Scicluna 2002).  
 
A Spanish study suggested that the prevalence of any kind of undesirable self-
medication in Spain was 2.5%. Prescription medicine use without prescription was 
most common among students, persons older than 40 years and those who lived 
alone (Figueiras et al. 2000). A more recent Spanish study examined 
pharmacists´ opinions about selling prescription medicines without a prescription. 
Altogether, 83.5% of these pharmacists reported dispensing prescription 
nonsteroidal anti-inflammatories, 65.9% antibiotics, 46.3% ACE inhibitors and 
13.4% benzodiazepines without a prescription (Caamano Isorna et al. 2004). This 
low prescription requirement was associated with pharmacy ownership and size 
(pharmacists per pharmacy) and with the high economic level of the population. In 
addition, the pharmacists´ workload and pharmacists' overestimations of their own 
qualifications to prescribe were associated with this practice (Caamano Isorna et 
al. 2004, Caamano et al. 2005). In another study prescription medicines were 
requested without prescription in 11.1% of the cases and dispensed in 10.8% of 
the cases (Barbero-Gonzalez et al. 2006).  As undesirable self-medication has 
become a challenge in Spain, the authorities have begun to enforce the 
regulations strictly (Jubete Vazquez 2004, Scrip 2005).  
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5.2 Factors influencing the decision to self-medicate 
 
There are several factors affecting self-medication behaviour. Symptom severity, 
earlier experiences with medicines and diseases and personal characteristics and 
attitudes affect decision-making on whether to contact health care professionals 
or to self-medicate (Sihvo 2000). This decision also relies on availability and 
access to health services and on the time which people have available. The social 
environment, family and friends as well as their earlier experiences and beliefs 
may affect the decision (Sihvo 2000). In addition, external information sources, 
such as advertising, the media, the Internet as well as contacts with pharmacists 
and other health care professionals may affect the decision (Sihvo 2000). Cultural 
aspects as well as policy decisions on the medicines available for curing minor 
symptoms may also affect the decisions. 
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6 MIGRANTS WITHIN THE EUROPEAN UNION 
 
 
Migration within the European Union is not new. For decades, people have moved 
from the Northern European countries to Southern European countries such as 
Spain, Italy and Greece. In Spain, the number of foreign residents has increased 
significantly in the last quarter century (Table 8, Ortega Pérez 2003). Even though 
the number of immigrants from developing countries has increased rapidly, 
residents from European countries are the second largest group of foreign 
residents in Spain (Table 8). 
 
 
Table 8. The number of official foreign residents/immigrants in Spain in 2000 and 
2006 (Ministerio de Trabajo y Asuntos Sociales 2000,2006) 
 
 
 
 
Previously, the largest resident groups in Spain from EU countries were British, 
German and Italian, but the situation has changed during the last few years: the 
number of people from new EU member states (e.g., Romania, Bulgaria, Poland) 
has increased, and in 2006 the number of Romanian people surpassed the 
number of people from Britain, Germany or Italy. Figure 5 shows the largest 
resident groups from EU countries and Norway in 2006. These numbers, 
however, should be viewed with caution as they only represent the people who 
are officially registered. Estimates of the actual number of migrants living in Spain 
vary for numerous reasons, for example, because of seasonal migration, 
difficulties with the bureaucracy, lack of clarity about reporting requirements and 
tax issues (Hardill et al. 2004).  
 
CONTINENT OF ORIGIN  YEAR 2000 YEAR 2006 
   
Europe 
EU countries 
360,007 
311,219 
1,028,678 
   661,004 
Latin America 184,944 1,064,916 
Africa 261,383    709,174 
Asia  72,447     197,965 
Oceania        902        1,819 
North America   15,020      18,109 
Not available     1,017         1,147 
TOTAL 895,720 3,021,808 
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Figure 5. Largest official resident groups in Spain from EU countries and Norway 
in 2006 (Ministerio de Trabajo y Asuntos Sociales 2006). Romania and Bulgaria, 
which joined the EU in the beginning of 2007, are also included in the figure. 
 
 
 
Instituto Nacional de Estadistica statistics show that 40% of the British, 29% of 
German and 24% of French nationals living in Spain are more than 50 years old. 
However, these statistics include only the registered population and, for example, 
those who are employed in Spain are more likely to be registered than are 
pensioners. The British study suggested that two-thirds of British migrants settled 
in their destination area are between ages 50 and 64 (Casado-Diaz et al. 2004). 
In this study, four southern areas were examined and those who settled in the 
Costa del Sol region of Spain tended to be slightly older than migrants to other 
areas. Nearly 80% of migrants to the Costa del Sol region settled there after they 
had turned 50 years old (Casado-Diaz et al. 2004). The studies, which 
concentrated only on retired migrants, showed that the respondents were 
relatively young seniors, the overall average age being 66 years. More than 42% 
of these migrants were aged 65-74 and only 19 per cent were older. Two studies 
made in the Costa del Sol region suggested that men were a slight majority, at 
51% and 52% of the respondents (Casado-Diaz et al. 2004). The two studies also 
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recorded the highest educational level of the respondents, one suggesting that 
19% and the other that 41% of the respondents had a university-level education 
(Casado-Diaz et al. 2004). 
 
The migrants are not a clearly identifiable group, since individuals are moving 
back and forth all the time; some migrate temporarily and others take up more 
permanent residence (Warnes et al. 1999, O´Reilly 2000, Huber and O´Reilly 
2004, Warnes et al. 2004). The migrants overall can be categorised into the 
following groups: short term-visitors; employees/working residents; retired 
residents/pensioners; and the “floating population”. Floating population or “false 
tourists” are residents who stay in Spain for more than three months of the year, 
but without registering with the authorities (Rosenmöller and Lluch 2006). 
Retirement migration has increased since its emergence in 1960 (King et al. 
1998). Retirees are moving to regions where they believe their quality of life will 
improve during their older age (King et al. 1998). Many of these retired migrants 
have lived in Costa del Sol for more than 30 years, while others have just recently 
settled. The number and characteristics of retired migrants is difficult to assess as 
this group comprises both registered migrants and the floating population, which 
is unrecorded in official statistics (Williams et al. 1997, King et al. 1998). This 
floating population travel back and forth between Spain and their home countries, 
and because of the informality of their status, their numbers are difficult to 
estimate or even approximate. For example, in Valencia, 73,000 residents held 
official residence cards, and 158,000 had registered in the municipalities, but a 
significant proportion was not registered at all (Rosenmöller and Lluch 2006). In 
addition, the official number of Swedes residing in Spain is about 10,000, but it 
has been estimated that the actual number is somewhere near 40,000; and 
although the official number of British people in Spain is less than 200,000, almost 
a million own Spanish property where they live at least part of the year 
(Blakemore 1999, Hardill et al. 2004). 
 
Migrants in mass tourist areas have little or no need to learn the local language, 
as many of the commerce and personal services are offered in their native 
language (this does not include all health services) (Casado-Diaz et al. 2004). 
However, many hospitals have realised the language problem and have included 
language skills as a criterion when hiring new staff (Rosenmöller and Lluch 2006). 
The two studies made in Costa del Sol suggested that 4% and 28% of migrants 
were fluent in Spanish, while 11% and 71% knew only a few words or had no 
language skills at all (Casado-Diaz et al. 2004).  It is also known that many 
Swedes living in the region speak relatively little Spanish because they live among 
expatriates and have only limited contacts with Spanish residents (Gustafson 
2001).  
  70 
6.1 Reasons for migration 
 
Most commonly migration is directed to Southern European countries in or close 
to mass tourists zones where the migrants may have stayed during previous 
tourist visits.  The location of the second home may also influence decisions on 
where to settle (Bell and Ward 2000, Rodriguez 2001, Casado Diaz et al. 2004).  
Climate and other environmental factors are the most commonly cited reasons for 
making the move (Casado-Diaz et al. 2004). The Mediterranean winter climate, 
which enables outside activities, attracts many migrants. These activities are also 
connected to health, for example, a Swedish couple reasoned that they would 
surely have a longer life living in Spain than if they were spending the winters 
indoors in Sweden (Gustafson 2001). Financial advantages are the second most 
prevalent of the reasons expressed, even though the cost-of-living differential 
between Southern and Northern European countries has declined in recent years. 
Even though prices have risen, they are still found to be affordable. The prices of 
housing, in particular, are lower than in big cities in the Northern countries. In 
addition, the harmonisation of democratic, civic and legal frameworks has made 
property purchases more secure and attractive (Warnes et al. 2004). As the 
number of migrants has increased, many services are being offered in the 
migrants´ native language or in English, which makes daily life easier for those 
who have no or only modest language skills. Many people are also attracted to 
the Mediterranean way of life, and it is reported anecdotally that the social life and 
leisure activities have affected the migration. The improved access to the 
Mediterranean by frequent flights and budget airlines has enabled hundreds of 
thousands of people to visit and experience the region. The technological 
changes in telecommunications, cable television and information networks have 
also increased the movement (Warnes et al. 2004). 
 
 
6.2 Mobile patients  
 
6.2.1 Mobile patients in the European Union 
 
Patient mobility has recently arisen on the Health Policy agenda in the EU 
(European Commission 2003c, 2003d, 2004). In 2002 the Commission brought 
together health ministers from across the EU with representatives of patients, of 
professionals, of providers and purchasers of health care and of the European 
Parliament in a high-level reflection process (European Commission 2003c, 
2003d, 2004). This process issued a report that included 19 recommendations in 
five main areas: 1) European cooperation, 2) information 3) access and quality 4) 
reconciling national objectives with European obligations and 5) the Union’s 
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cohesion and structural funds (European Commission 2003c, 2003d, 2004, 
European Union 2006, Rosenmöller et al. 2006). The Commission responded to 
these recommendations and defined the areas of work. The Commission also 
recommended the creation of a High Level Group on Health Services and Medical 
Care, which would develop working groups on different issues such as cross-
border health care, information, e-health and patient safety (European 
Commission 2003d, 2004). 
 
Since the Treaty of Amsterdam in 1997, health systems have been the matter of 
national governments. In recent years, however, the increasing need for internal 
markets and international co-operation in health services have been discussed. 
Health services were excluded from the European Union Services Directive 
(2006/123/EC) in 2006. 
 
Community law provides citizens with the right to seek healthcare in other 
member states and be reimbursed (European Commission 2004). The European 
Court of Justice has clarified the conditions under which a patient may be 
reimbursed in another member state (Palm et al. 2000, European Commission 
2004). Community law also provides citizens with rights to health care in other 
member states when they move. However, citizens may not always know their 
rights and obligations (European Commission 2004). At the moment, citizens of 
the EU member states have a right to move and reside freely among the member 
states. The freedom of movement requires that people travelling within the EU be 
allowed to obtain all necessary health services during their visits. This has been 
resolved by European Council Regulation (EEC) No 1408/71 with its 
implementing regulation (Council regulation (EEC) 574/72 and with Regulation 
(EC) No 883/2004. Regulation  (EEC) No 1408/71 established the E111 system, 
followed by the European Health Insurance Card (EHIC) (Decision 2003/753/EC, 
Rosenmöller and Lluch 2006). EHIC cards provides reduced-cost or free access 
(depending on state regulations) to any treatment that becomes necessary during 
visits to other EU/EEA countries or to Switzerland. In practice, this means that 
patients are treated so that they do not have to return prematurely to their country 
of origin to receive treatment.  
 
The E112 system was established to enhance the benefits of collaboration across 
borders. The E112 form is used as pre-authorisation for the citizen of an EEA/EU 
country or Switzerland who will have planned treatments abroad (European 
Commission 2007b). The treatments may include hospital or other kinds of 
medical treatment. In the case of hospital treatment, pre-authorisation is needed 
in order to receive reimbursement. Other types of treatments may be reimbursed 
retroactively. In such cases the treatment will be provided in conditions similar to 
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those applying to residents. There are also other agreements between individual 
countries, although the agreements do not provide a clear framework, and in 
some cases unresolved issues have proceeded to the European Court of Justice 
(Palm et al. 2000).   
 
 
According to Rosenmöller et al. (2006), mobile patients can be divided into five 
categories: 
 
1) Those who are on holiday and need to use of health care services in the 
country they are visiting 
2) Those who retire in a different country and wish to use the health services 
3) People sharing close cultural or linguistic links with the region where care is 
provided 
4) Patients who cross a border to receive health care or buy health goods, 
i.e.,  “medical tourism” 
5) Patients who are sent abroad by their own health system to overcome its 
capacity restrictions  
 
Most migrants in Southern European countries, such as Spain, are included in the 
first two groups. Those who are using EHIC are provided the necessary health 
care. The health care is provided only within the Spanish State Health Service. 
Those who spend more than 90 days in Spain are required to register in person at 
the Foreigners' Office. Official residents are entitled to the same healthcare as 
Spanish citizens, and they will be registered in the population registry. However, 
those official residents who are transferring their rights to the Spanish system 
retain their rights to also use health services in their country of origin. If they need 
health services while visiting their country of origin, they may use the EHIC or 
apply the pre-authorisation (E112) from Spain to use planned health services in 
their country of origin. Spanish health care guarantees access to medical attention 
and assistance in hospitals, but post-hospital assistance and home-care is scarce 
in Spain. This is problematic for those who do not have relatives living nearby 
(Rosenmöller and Lluch 2006). Consequently, many seasonal migrants rely on 
the EHIC system as they are afraid of losing their rights at home. Some migrants 
also have private health insurance, so that they would not have to transfer their 
rights in order to secure long-term health care (Hardill et al. 2005). 
 
 As many retirees are living with a foot in either country, they may feel that they 
are falling through the cracks. They are no longer the responsibility of their home 
country, yet the new country may also be unable to provide them with all of the 
services they need (Hardill et al. 2005). Some evidence suggests that cross-
border health care is not consistently of high quality and may not always meet the 
needs of patients, especially when the patient does not have language skills or 
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does not understand the local health system (Rosemoller et al. 2006). Previous 
studies have suggested, that many migrants did not transfer their rights, but used 
the E111 form to access health care when needed. Even hip replacements have 
been made under E111 (Rosenmöller and Lluch 2006). This floating population, 
however, complicates the improvement of health services in migrant areas. 
Without knowing the actual profiles of residents living in the area, the allocation of 
resources would become difficult (Hardill et al. 2004). Under-registration can thus 
lead to under-funding of health care services in the migrant areas, leading to a 
lack of resources in the hospitals and in healthcare overall. On the other hand, the 
existing registers are incomplete. They lack basic information on, e.g., the type of 
care provided and its costs. The latter leads to a large cost burden on Spain's 
public finances (Rosenmöller and Lluch 2006). There has also been a widespread 
view in Spain that retired people from other EU countries are all very well-off, and 
it would not be right to improve the care of this group at the expense of Spanish 
citizens (Hardill et al. 2004). The survey made by Rodriguez et al. (1998) 
suggested that Scandinavian retirees in Spain are mostly upper middle-class, but 
other studies have found that there are retirees from different socio-economic 
backgrounds as well (Casado-Diaz et al. 2004).  
 
Under-registration complicates the study of migrants and of their use of health 
services. Many studies have concentrated on young people and workers, but they 
do not offer information about the needs of older populations. The older 
population has greater needs for health services, and they have a growing 
influence on health and social welfare policies and legislation (Warnes et al. 
2004).  Even though many retired migrants have not registered with the system, 
they still have health care needs beyond primary care, such as care for chronic 
conditions, screening, health promotion and disease prevention (Rosenmöller and 
Lluch 2006). In some areas of Spain, private health care providers count on 
tourists´ willingness to pay, and tourists are often advised to use private clinics, 
where the EHIC does not cover the charges (Rosenmöller and Lluch 2006). 
Tourists and migrants are often poorly informed and confused about their rights.   
 
Most of the studies on retirement migration have concentrated on estimating the 
size of the migration population, the reasons for migration and the impact of the 
migration in the receiving areas (Williams et al. 1997, Rodriguez et al. 1998, 
Williams et al. 2000, Gustafson 2001). In addition, most of the studies concern 
migrants who are in good health, but there is a lack of information concerning 
migrants’ health status, use of, and quality of used, health services and the 
problems involved. Some studies suggest that migrants have more health 
complaints than non-immigrants; that they seek care for common symptoms more 
often and expect a medical intervention from their general practitioner more often 
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than do the non-immigrants. However, these studies have not concentrated on 
migrants within the EU (Bradley et al. 2004, Weilandt et al. 2006). Dutch studies 
suggest that migrants do, on average, have a lower health status than does the 
non-immigrant population and that they visit general practitioners more often 
(Stronks et al. 2001, Uiters et al. 2006).  Specialised healthcare use is lower 
among immigrant groups, and there has been a debate over whether limited 
access to these services may be an explanatory factor, since it is known that 
specialised services may be more expensive and that ethnic minorities more often 
represent a lower income group than that of non-immigrant populations (Smaje 
and Grand 1997, Cooper et al. 1998, Stronks et al. 2001, Saxena et al. 2002). 
The results of a British study, however, suggest that the health status reflects the 
use of health services rather than the ethnic group.  
 
Some studies also suggest that immigrants are healthier than the non-immigrant 
population. This phenomenon is known as the healthy immigration effect, and it 
has been observed in the U.S., Canada, Australia and in Western Europe 
(Fennelly 2005).  Studies conducted in the U.S. show that first-generation 
immigrants are often healthier than people of the same ethnic origin who were 
born in the U.S. (Singh and Siahpush 2001). The study of Muening and Fahs 
(2002) suggests that foreign-born residents are healthier, have longer life 
expectancy and have lower healthcare costs for the society than the non-
immigrant population. These health advantages seem to diminish over time, and 
in the U.S., this has been explained by environmental factors such as poverty, 
poor housing and barriers to access healthcare; as well as by behavioural factors 
(unhealthy diet, tobacco, alcohol and drugs) (Fennelly 2005). 
  
 Migrants from other EU countries may have different needs for health services 
than the non-immigrant population. The health care systems as well as the 
pharmacy systems differ between European countries (Vogler et al. 2006). For 
example, when people age in Northern European countries, there is a relatively 
high provision of social services (Hardill et al. 2004). People are accustomed to 
receiving home care and nursing home care, but similar arrangements do not 
exist in Spain. In Spain, there are a growing number of migrants who are unable 
to support themselves as a result of either health problems or lack of finances 
(Hardill et al. 2005). The lack of language skills does not help the situation, and 
the lack of systematic research evidence has created false expectations about the 
daily life of the migrants (Hardill et al. 2005).  
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7 CONCLUSIONS OF THE LITERATURE REVIEW 
 
 
The role of community pharmacies as providers of primary health care services is 
not well understood. In Europe, people often use pharmacies to find relief for 
minor illnesses and as a possible prelude to seeing a general practitioner, but in 
some countries, pharmacies are also used as a substitute for general practitioners 
or for other health services.  Overall, pharmacies are often the first place of 
contact in the symptom mitigation process. However, community pharmacy 
services vary within the EU. In the EU, there is no harmonised pharmaceutical 
policy concerning community pharmacy practices (Figure 6), nor are there any 
minimum standards for community pharmacy services, although WHO, FIP, and 
national pharmacy associations have made recommendations and offered their 
views on the role of pharmacists and pharmacy services. 
 
As migration, and especially retirement migration, has increased in recent years, 
the number of elderly and chronically ill mobile community residents is also 
increasing.  As these people may suffer from multiple health problems, they will 
make demands on the local health care services. Even though hospitals and 
private clinics have started to offer services for mobile community residents, the 
actions of community pharmacies have been negligible. It would be important to 
understand migrants’ characteristics, their health seeking and medication 
behaviour, and the role of the pharmacy in their health seeking process in order to 
develop the pharmacy services of migrant areas, as well as all over the EU, to 
meet the needs of mobile community residents. 
 
There is no harmonised policy in community pharmacy issues in EU and the 
community pharmacy practices vary between member states. As the amount of 
mobile community residents is increasing, there is a need to study how 
community pharmacies in EU are capable in providing adequate services to 
mobile community residents (Figure 6). 
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Figure 6. Summary of the literature review 
 
 
 
Access to 
medicines
Use of
medicines
Quality of
services
Role of the 
pharmacy
Prices of 
medicines
NEED TO STUDY HOW COMMUNITY PHARMACIES
IN EU ARE CAPABLE IN PROVIDING
ADEQUATE SERVICES TO MOBILE COMMUNITY 
RESIDENTS
No 
harmonised 
pharmaceutical 
policy in community
pharmacy issues 
in the EU
Pharmacy 
services
  77 
8 AIM OF THE STUDY 
 
 
The aim of the study was to understand use of medicines, symptom mitigation 
and the role of community pharmacies in this process from the perspective of 
mobile community residents within EU. In this study, Finns living in Spain were 
used as an example. The specific study objectives were: 
 
1. To describe the Finnish immigrant population in the Spanish Costa del Sol 
region and to study the extent of health immigration (I) 
2. To study medication usage habits of the Finnish immigrant population in 
Spain (I,II) 
3. To survey the opinions of the Finnish residents about community pharmacy 
services and possible risks related to access and use of medicines in Spain 
(III) 
4. To describe the role of community pharmacies in the symptom mitigation 
path of mobile community residents (IV) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Study flow 
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9 MATERIALS AND METHODS 
 
 
In this study, both quantitative and qualitative methods were applied (Figure 7), a 
process known as triangulation (Mays and Pope 1995, Eskola and Suoranta 
1998). The term triangulation is used when different types of approaches, 
methods or data are used in the same research (Eskola and Suoranta 1998, 
Smith 2002). Qualitative and quantitative methods can be used in combination in 
several ways (Hirsjärvi et al. 1997): 
 
• Qualitative study can be used as a pilot study for quantitative study 
• Qualitative methods can be used in parallel with quantitative methods 
• Quantitative study can come before qualitative study.  
 
The aim of quantitative methods is to gather a sample of sufficient size according 
to a valid procedure leading to reproducible findings that can be generalised to the 
wider population.  The methods include both descriptive and inferential statistics 
(Smith 2002).  In social pharmacy research, survey methods are common 
quantitative methods, the data being collected by interviews or by survey 
questionnaires (Smith 2002). In this study, a survey questionnaire was used to 
gather descriptive information about the Finnish population in the Costa del Sol 
region of Spain, to characterise the population, to describe their medication use 
habits and to describe their views and attitudes about community pharmacy 
services. 
 
The outcomes of qualitative research differ from those of quantitative methods.  
The idea in qualitative research is to develop a deeper understanding of the 
rationales (the why's), processes (the how's) and context (the when's) of the 
phenomena under investigation (Lehoux et al. 2006). The main idea is not to 
generalise the findings, but to describe the phenomena in a particular context and 
time. In this study, the qualitative research supplemented the quantitative study.  
The idea of focus group discussions was to provide a deeper understanding of the 
issues that emerged from the survey and to create a more comprehensive picture 
of the study objectives as a whole. By using focus group discussions it is possible 
to gain access to views that would be elusive in the survey design. The group 
dynamics of focus groups are important for revealing potential controversies, and 
in this case, belonging to a group of mobile patients provided participants with the 
opportunity to explore arguments and clarify their own views on this new and 
complex issue. As all methods have their limitations, combining these two 
methods yielded a more complete view on the study subject and enhanced the 
validity of the data (Pope and Mays 1995, Smith 2002).  
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9.1 Quantitative study (I-III) 
 
9.1.1 Study design 
 
The target population of the study were Finnish immigrants who reside at least 
part of the year in Spain, in the Costa del Sol region. Finns were chosen as a 
example population, because it was known that thousands of Finns reside in 
Costa del Sol and represent a typical group of Northern Europeans that move into 
Southern European countries such as Spain. The differences between community 
pharmacy practices in Spain and Finland were another reason why Finns were 
chosen as an example. The Finnish pharmacy system is strictly regulated, and it 
emphasises professional practices (Medicines Act 395/1987). Finns as customers 
are used to practices where pharmacists may dispense either prescription 
medicines by a prescription or non-prescription medicines for minor symptoms. 
Dispensing should be accompanied by medication counselling to assure proper 
and safe use of the medicine. There are other situations where the pharmacists` 
main professional assistance to patients is not a product but a service, e.g., 
advice to patients on managing their symptoms without medicines or a 
recommendation to seek care from a physician.  In Spain the system is different. 
Previous studies have suggested that customers there may have more influence 
in the management of their conditions because in some cases customers have an 
option to buy prescription medicines directly from the pharmacy (Figueiras et al. 
2000). 
 
The exact number of Finns in Spain is unknown, as many of them are not 
registered in the official registries. Because of the lack of a precise sampling 
frame, it was decided to take a convenience sample of the population. Based on 
the previous knowledge, several years experience and three months observations 
in the region, it was known that Finnish immigrants actively use services 
(restaurants, churches, associations) that are offered in their native language. It 
was also known, that Finnish newspapers were sent to hundreds of Finnish 
people living in Costa del Sol. The sample method was determined on the basis of 
previous knowledge and reports from previous studies of EU migrants (Casado 
Diaz et al. 2004, Karisto 2005). These surveys also were faced with the 
unavailability of a precise sample frame. The sample size was determined on the 
basis of information from a previous study performed among Finns living in Spain, 
and statistical calculations were based on an estimated population of 15,000 
(Karisto 2005). 
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One thousand (1,000) copies of a questionnaire were distributed in two ways: half 
(500) of the questionnaires were distributed by mail with Finnish newspapers and 
the other half through Finnish associations and outlets (e.g., churches, cafes, 
restaurants, communities) in Southern Spain. The researcher visited each of 
these associations and outlets and explained the idea of the study. These visits 
continued each week during the data collection, so that questions about the 
questionnaire could be raised and resolved. The telephone number of the 
researcher was also available in the questionnaires so that the researcher could 
be contacted in case of questions. The 16 associations and outlets were asked to 
distribute the questionnaires (with return envelopes) to individuals using their 
services. The questionnaire could be brought back either to return boxes of the 
associations or by mail to the researcher. The researcher advertised the study 
twice in local Finnish newspapers and once on Finnish Radio in order to raise 
publicity.  The quantitative data (studies I-III) were collected in spring (February 
15th—April 15th) 2002.  Of the 1,000 questionnaires delivered, 533 were 
completed and returned (response rate 53%).   
 
9.1.2 Questionnaire  
 
A 12-paged semi-structured questionnaire was used (Appendix 1). Based on the 
literature review, there is no previous study focused on immigrants and pharmacy 
services. Therefore, most of the questions in the survey instrument were 
developed for this study. However, some of the questions were adapted from 
previously used questionnaires (e.g., those concerning background variables such 
as gender, age, marital status, and those measuring state of health and 
occurrence of symptoms) – in particular, the Finnish National Public Health 
Institute’s questionnaires on Health Behaviour and Health Among The Finnish 
Adult Population and Health Behaviour Among the Finnish Elderly (Sulander et al. 
2001, Helakorpi et al. 2002). Most pharmacy-practice researchers have 
developed their own survey instruments, but it is also common to use or modify 
questions or question series from previous questionnaires (Smith 2002). To 
enhance validity and reliability, the questionnaire was first piloted with ten Finns 
living in Spain (Fowler 1995, Smith 2002). Based on the results of this pilot study, 
some questions were clarified and rewritten. 
 
The questionnaire included questions about the following subjects: 1) background 
variables, 2) health status, 3) experience with community pharmacy services, 4) 
use of medicines in general, 5) use of antibiotics, 6) use of analgesics, 7) arthritis, 
8) coronary heart diseases, and 9) asthma. The use of antibiotics was included as 
it was known that antibiotic resistance is increasing and that non-prescription use 
of antibiotics had occurred in Southern European countries such as Spain (Mason 
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1999, Figueiras et al. 2000). Pain is a very common symptom worldwide and 
analgesics use is common among Finns (Turunen 2007). Therefore, analgesics 
use was selected for the study. The specific disease categories were selected 
because they are generally known to be Finnish public-health diseases, and 
previous studies had also suggested that climate may have effect on the 
symptoms of these diseases (Guedj and Weinberger 1990, Rostand 1997, 
Helakorpi et al. 2002, Verlato et al. 2002). All respondents answered questions in 
the first four sections. In the latter sections, respondents were instructed to skip 
questions if they had no experience of the subject.  
 
The background variables included gender, age, duration of time living in Spain, 
marital status, educational background, working situation, state of residency and 
the use of health services. Health status was determined based on questions 
about chronic morbidity and symptoms that had occurred during the previous 
weeks. The use of medicines in general was studied by asking questions about 
medicines used, symptoms related to medicine use and medicine use habits and 
perceptions. 
 
9.1.3 STUDY 1. Health immigrants and analgesic use 
 
The aim of this study was to describe immigration within the EU; determine the 
proportion of Finnish people who have moved to Spain for health reasons (health 
immigrants) and determine whether their health care and analgesic usage 
patterns differed from those of non-health immigrants. Respondents who indicated 
that health factors played a significant or moderate role in the migration process 
were categorised as health immigrants. If health-status factors did not affect the 
migration, the person was categorised as a non-health immigrant. The survey 
respondents were also categorised into analgesics users and non-users. 
Analgesic use was defined by asking whether respondents had used analgesics 
during the previous two weeks (i.e., 14 days). Those who indicated use of 
analgesics in the previous two weeks were defined as users and were asked 
specific questions about their analgesic use. Non-users were instructed to 
continue with questions from other sections. The purpose of this categorisation 
was to minimise the incidence of recall bias in questions about analgesic use. 
Information about the use of different Rx and OTC analgesics was gathered with a 
structured question: “Which of the following analgesics have you used during the 
previous two weeks?" After the ingredient names, some of the most common 
brand names were given to facilitate answering. The last alternative was “any 
other”, which the respondents were instructed to specify (Appendix 1). The list of 
analgesics was created based on the Finnish Medicine Statistics 2000 in order to 
incorporate the most commonly used analgesics in Finland. Factors associated 
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with analgesic use were examined by asking questions to determine background 
variables (listed earlier). In the analysis, the pensioners and part-time pensioners 
were grouped together. Language skills as well as the use of public health 
services were assessed. Three types of questions were asked to determine the 
respondents’ current health status, and these concerned: 1) health status, 2) 
chronic morbidity, and 3) the symptoms during the previous two weeks. 
Respondents were asked to categorise their health status as good, moderate or 
poor.  They were also asked whether they had suffered from chronic morbidity 
and to list the symptoms they had suffered in the previous two weeks. Statistical 
analyses were conducted using the statistical software SPSS 11.5 (Statistical 
Package for Social Sciences). Cross-tabulation was used to compare different 
groups. Statistical comparison was done by chi-square testing, with p-value <0.05 
considered significant.   
 
9.1.4 STUDY 2. Antibiotic use via self-medication 
 
The aim of this study was to determine the frequency of self-medication with 
antibiotics among the Finnish adult population living in Southern Spain. The 
population was divided into antibiotic users and non-users by asking “Have you 
used antibiotics during the previous six months?” Those who answered “yes” to 
this question were defined as users and continued answering the more specific 
questions about their antibiotic use. Non-users did not answer the antibiotic 
questions. The purpose of this categorization was to ascertain the validity and 
minimise the incidence of memory bias in questions about antibiotic use. Antibiotic 
users were asked whether they had bought antibiotics pursuant to a physician’s 
prescription (Prescription-antibiotics) or without prescription (OTC). Those who 
had used both prescription and OTC antibiotics were categorised as non-
prescription antibiotic users. Respondents reported the number of antibiotic 
prescription courses taken and the name of their used products (when 
remembered). The purpose of the antibiotic use was asked by giving a list of the 
possible indications. The last alternative was “any other purpose” with 
respondents instructed to specify them. To gather some information about the 
effectiveness of antibiotics, the users were asked whether the first antibiotic 
course relieved their symptoms. They were also asked how many courses they 
had to take before healing. The occurrence of adverse reactions was determined 
by giving a list of the possible adverse reactions to antimicrobial therapies that the 
respondents may have experienced.  The list included adverse reactions known 
as typical for antibiotics and the last category of response was open, i.e., the 
respondent could specify any other adverse reactions. Asking questions about 
background variables and health state identified the factors associated with 
antibiotic use: sex, age, marital status, working situation, smoking, health state 
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and chronic morbidity. The data were analysed with SPSS version 11.5 (Statistical 
Package for Social Sciences). In the analysis, the working situation was 
reclassified so that the pensioners and partial pensioners were grouped together. 
Cross-tabulation was used to compare differences between subgroups. To 
examine the factors related to antibiotic use, statistical comparison was 
implemented using logistic regression analysis. The adjusted prevalence ratios 
and their 95% confidence intervals were analysed. The variables which were 
included in the analysis were age, gender, marital status, working situation, self-
reported health, chronic morbidity and smoking. 
 
9.1.5 STUDY 3. Pharmacy services  
 
The aim of this study was to assess Finns opinions of Spanish pharmacy services 
and their perceptions of risks related to access and use of medicines. The 
questionnaire included both structured and open-ended questions concerning 
their experiences with community pharmacy services in Spain. Based on their 
own experiences, the participants were asked to rate their satisfaction with the 
following areas of pharmacy services: customer service, counselling on 
prescription and non-prescription medicines, knowledge and language skills of the 
pharmacy personnel (in general), and the assortment of medicines available in the 
pharmacy’s inventory.  Responses were scored on a 5-point Likert-type scale (1 = 
highly dissatisfied, 5 = highly satisfied, including the neutral intermediate choice = 
3). In the open-ended questions, respondents were asked: a) which aspects of 
Spanish pharmacy services they preferred compared to Finnish pharmacy 
services (and vice versa); b) whether they had encountered problems during visits 
to pharmacies in Spain and, if so, what kind(s) of problems; and c) how important 
was it that pharmacy services in Spain be offered in their native language.  These 
study questions were created based on the results of the previous pharmacy 
services study conducted in Finland (Airaksinen 1996). The data were analysed 
with Statistical Package for Social Sciences version 11.5 (SPSS). Descriptive 
statistics of the sample characteristics, background variables and questionnaire 
items were computed. The open-ended questions were analysed using content 
analysis. An experienced Finnish pharmacist, who was knowledgeable about the 
Spanish pharmacy system, independently reviewed the open-ended responses 
and derived similar themes to those identified by the primary researcher. 
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9.2 Qualitative study (IV) 
 
The fourth study was conducted by using focus group discussions (FGDs). Focus 
groups are is an effective and interactive way to interview people (Eskola and 
Suoranta 1998). It was decided to use focus groups because of their ability to 
capture people’s experiences, attitudes and opinions about the study subject. 
FGDs are also useful for gathering information about subjects in cases where little 
is known previously. The group setting helps people to explore their own thoughts 
and experiences in order to produce more complete responses (Eskola and 
Suoranta 1998). Also shy group members might be stimulated enough by other 
people’s opinions to volunteer their own (Eskola and Suoranta 1998).  Focus 
groups have previously been used to analyse the experiences of other health care 
users, and therefore this method was chosen to collect data about pharmacy 
services (Lehoux et al. 2006).  
 
9.2.1 STUDY 4. The role of the pharmacy in the symptom mitigation 
 
The survey provided information about the characteristics of the Finns living in 
Spain, their medication use habits and experiences with pharmacy services.  By 
conducting focus group discussions, it was possible to deepen the information 
that emerged from the survey in order to create a more comprehensive picture of 
the role of the pharmacy in the symptom mitigation process of mobile community 
residents. The interview guide included questions about Spain’s pharmacy 
system, the pharmacy’s role in the healthcare system and the health seeking 
behaviour of mobile community residents (Appendix 2).   
 
The data were collected by conducting five FGDs among Finnish people living in 
Costa del Sol. Five FGDs were conducted in different locations in Southern Spain. 
The participants were well informed about the study procedures and they had a 
right to refuse their participation. Five contact persons chose the participants so 
that the inter-group dynamics were consistent in order to create natural 
surroundings. However, the groups themselves were different, representing 
different socio-economic strata from different locations in Costa del Sol (these 
included: a higher socio-economic group, i.e. "the golfer group"; a lower socio-
economic group, i.e., "the pub group"; a church activist group; a suburban 
community-activist group; and a group of who were caregivers to their close 
relatives. The group size varied from 5-8 participants. Altogether there were 30 
participants, and their age varied from 57-83 years (mean 68 years). Their 
duration of residency in Spain varied from 1-19 years (mean 8 years). A majority 
(83%) of the participants suffered from chronic morbidity, and the same proportion 
of people used Spanish health care services. Half of the participants bought their 
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medicines from both countries (Finland and Spain), 33% mainly from Spain and 
13% mainly from Finland. One-fourth of the participants had some Spanish 
language skills, while 43% described only having Finnish language skills. 
 
Two researchers were present during the five focus group interviews: one served 
as a moderator and the other as an observer and a note-keeper. Each session 
lasted around one hour, and they were tape-recorded and transcribed verbatim. 
The data was processed confidentially and the results are expressed so that no 
individuals can be identified.  The analyses were done by the researcher (MV), but 
they were continuously discussed with the note-keeper during the process. This 
was done to validate the emerging themes and findings. Both inductive and 
deductive analysis was used (IV: Figure 1.). Deductive analysis was used to 
determine themes related to the pharmacy’s role in health care and in order to 
study the themes that emerged from the data: inductive analysis related to the 
mobile patients´ attitudes, opinions and experiences with pharmacy services.  
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Table 9. Methods used in original publications (I-IV) 
 
Study Aim of the study Method Analysis 
I • To describe the 
Finnish immigrant 
population living in 
Costa del Sol region, 
Spain 
• To study the 
proportion of 
immigrants who 
moved to Spain for 
health reasons (health 
immigrants) 
• To study analgesic 
use among Finnish 
immigrants 
• To study whether 
health immigration 
influenced analgesic 
use 
Survey 
(n=533) 
Quantitative analysis 
SPSS 11.5 program 
• Chi-square test 
• Descriptive statistics on 
the sample characteristics, 
background variables, 
means, standard 
deviations and frequency 
distributions 
II • To study antibiotic use 
among Finnish 
immigrants in Spain 
• To determine the 
frequency of self-
medication with 
antibiotics and 
examine the factors 
related to the self-
medication 
Survey 
(n=533) 
Quantitative analysis 
SPSS 11.5 program 
• Chi-square test 
• Descriptive statistics on 
the sample characteristics, 
background variables, 
means, standard 
deviations and frequency 
distributions 
• Logistic regression 
analysis 
III • To survey Finnish 
immigrants opinions 
about pharmacy 
services and possible 
risks related to access 
and use of medicines 
 
 
 
Survey 
(n=533) 
 
3 open-
ended 
questions 
Quantitative analysis 
SPSS 11.5 program 
• Chi-square test 
• Descriptive statistics on 
the sample characteristics, 
background variables, 
means, standard 
deviations and frequency 
distributions 
•  Qualitative analysis 
• Open ended questions 
were analysed by content 
analysis 
IV • To describe the role of 
pharmacy in the 
symptom mitigation 
path of mobile 
community residents 
 
5 Focus 
group 
discussions 
(n=30) 
Qualitative analysis 
• Inductive and deductive 
analysis 
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10 RESULTS 
 
 
10.1  Health immigration and analgesic use (I) 
 
Seventy percent of the respondents (n=365) were categorised as health 
immigrants as they identified health reasons as having affected their decision to 
move to Spain (Table 10). Health immigrants differed in their personal 
characteristics compared to other immigrants; they more often reported suffering 
from chronic morbidity and they perceived their health status to be worse than did 
the non-health immigrants. Health immigrants also reported using more public 
health services and more often receiving reimbursement for their medicines than 
did the non-health immigrants (Table 10).  
  
Half of the respondents (50%, n=263) reported using analgesics during the two 
weeks before the query. The most commonly taken analgesics were ibuprofen, 
aspirin and paracetamol, and the most reported symptoms being treated were 
articulation pain, headache and common cold/fever. Health immigrants were more 
often analgesic users and they more commonly used prescription analgesics 
(diclofenac, naproxen, tramadol and nimesulid) than did the other respondents. 
Health immigrants also reported using analgesics more regularly than did the 
others, with daily use occurring among 27% (n=49) of the health immigrants and 
9% (n=6) of the others (p=0.02). The concomitant use of prescription and non-
prescription analgesics was also more common among health immigrants than 
the non-health immigrants (p<0.001). Altogether, the concomitant use of 
prescription and non-prescription analgesics occurred among one-quarter of 
analgesics users. There was no statistically significant difference in the 
purchasing behaviours between the groups; most of the respondents (55%, 
n=144) indicated buying analgesics both from Spain and Finland, 27% (n=70) 
from Spain and 18%, (n=47) from Finland. 
 
Among health immigrants, analgesic use was related to age, occurrence of pain 
symptoms and the length of residency in Spain. Analgesic use was decreased 
with age, but increased among those suffering from headache, joint ache or 
backache. Health immigrants who had lived in Spain 7-9 years had used 
analgesics more commonly than did residents of greater or less duration. Among 
the non-health immigrant group explanatory factors for analgesic use were age, 
occurrence of headache and joint ache, time of residency and employment.  
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Table 10. Characteristics of the respondents 
 
 
All 
respondents 
Health 
Immigrants 
Non-health 
Immigrants 
p-value 
between 
groups 
 
% n % n % n  
 100 533 70 365 30 157  
Gender 
       
Male 45 238 48 175 39 61  
Female 55 289 52 187 61 96 0.055 
        
Age 
       
Less than 45 3 13 1 2 7 11  
45-54 8 43 7 26 11 16  
55-64 35 183 37 133 31 47  
65-74 43 226 41 147 46 69  
75 or more 11 60 14 48 5 8 <0.001 
        
Working situation 
       
Employed  7 38 3 9 19 29  
Retired 86 453 91 332 73 113  
Other 7 35 6 22 8 12 <0.001 
        
Chronic morbidity 
       
Yes 69 355 82 290 39 59  
No 31 156 18 62 61 93 <0.001 
 
       
Perceived state of 
health 
       
Good 42 222 33 120 63 99  
Moderate  52 276 60 217 34 54  
Poor 6 30 7 26 3 4 <0.001 
        
Pain symptoms  
       
Backache 23 122 25 92 17 27 0.053 
Headache 17 89 18 67 14 22 0.255 
Joint ache 29 151 35 126 14 22 <0.001 
  
       
Years of living in 
Spain 
       
1-3 27 136 26 92 30 44  
4-6 25 128 26 91 24 35  
7-9 14 68 14 50 11 16  
10-14 24 120 23 81 25 36  
15 or more 10 52 11 37 10 14 0.777 
        
Use of public 
health services in 
Spain 
       
Regular  35 181 41 148 22 33  
Occasional 33 175 34 123 31 48  
No use 32 167 25 92 47 71 <0.001 
 
       
Reimbursement for 
analgesics 
       
No 51 136 46 89 72 46  
Yes 49 129 54 105 28 18 <0.001 
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10.2  Self-medication with antibiotics  (II) 
 
Of the respondents, 28% (n=145) had used antibiotics during the 6 month period 
before the query. Almost one-third (31%) of the antibiotic users had bought their 
antibiotics without a prescription, and 10% reported concomitant use of 
prescription and non-prescription antibiotics. Altogether 41% of the antibiotic 
users were using antibiotics as self-medication.  
 
Most of the antibiotic users (64%, n=93) reported the use of one course during the 
previous six months, 30% reported using two or three courses, and six per cent 
four or more courses. Statistical differences in the number of courses or their 
effectiveness could not be found between prescription and non-prescription 
antibiotic users. The first course was perceived to be effective by 69% of the 
antibiotic users. Clearly, the most common reason for the antibiotic use was 
common cold (Figure 8). This applied to both use prescribed by the physician and 
self-medication with antibiotics.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Reasons for antibiotic use and the proportions of self-medication 
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Antibiotics caused adverse reactions in 17% of the users. The most common self-
reported adverse reactions were stomachache/diarrhoea (5%) and dermatological 
problems (4%). Statistical differences in the prevalence of adverse reactions could 
not be found between prescription and non-prescription antibiotic users. 
 
Of the background variables, only chronic morbidity affected antibiotic use 
(p<0.05, 32% vs. 16%). No statistical differences could be found between those 
who had used prescription or non-prescription antibiotics.  
 
 
10.3  Finns’ experiences of community pharmacy services in 
Spain (III) 
 
Of the services offered by Spanish pharmacies, respondents were most satisfied 
with customer service, followed secondly by the pharmacy personnel’s 
knowledge, and thirdly by the assortment of medicines available (Figure 9).  The 
most dissatisfaction concerned the pharmacy personnel’s language skills. 
 
Respondents were more satisfied with counselling on OTC medicines than the 
counselling on prescription medications (58% vs. 49%). Satisfaction with OTC 
medication counselling, the language skills of the pharmacy personnel and the 
assortment of medicines available were associated with the Finnish respondents’ 
Spanish language skills and time of residency in Spain (p<0.05). In addition, 
dissatisfaction with prescription medication counselling was reported more often 
among those who had lived in Spain for 3 years or less (chi-square p<0.05).   
 
Altogether 60% of the respondents answered the three open-ended questions 
(n=318). Table 11 shows the positive and negative experiences with Spanish 
pharmacy services. 
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Figure 9. Satisfaction of the respondents with Spanish pharmacy services            
(% of those who had experiences with the service area) 
 
Table 11. Positive and negative opinions about Spanish pharmacy services 
 
Positive Negative 
 
- Easy access to all kinds of 
medication in the pharmacy, also 
prescription medications are sold 
without prescription 
- Less bureaucratic, flexible and 
customer friendlier than 
pharmacies in Finland 
- Cheaper prices (in 2002) 
 
 
- Medicines are too easily 
available, there should be stricter 
control 
- The professional skills and 
medication counselling of lower 
quality than in Finland 
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23
25
33
31
44
21
26
44
46
37
30
28
24
16
17
13
26
13
12
5
4
4
10
10
6
2
33
2
2
Pharmacists´ language
skills (n=440)
Counselling with Rx-drugs
(n=381)
Counselling with OTC-
drugs (n=421)
Medical assortment
(n=435)
Knowledge (n=447)
Service (n=456)
Highly satisfied Satisfied Neutral Dissatisfied Highly dissatisfied
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 Almost a fifth of the survey respondents reported experiencing problems during 
visits to pharmacies in Southern Spain; the lack of a common language caused 
most of these problems (n=51). In eight cases respondents reported receiving a 
prescription that contained a medication error. Most of these cases concerned a 
wrong medication from the pharmacy. Other problems concerned service, 
pharmacy workers’ knowledge, medicine stock and differences between Spain 
and Finland in approved medicines. Those who had experienced problems were 
more often suffering from chronic morbidity than were those who had not 
experienced problems (88% vs. 66%). They also described a worse state of 
health. Sixty-eight percent of those having problems had no Spanish language 
skills. Altogether, 43% of the respondents reported having at least some Spanish 
language skills. 
 
 
10.4  The role of the pharmacy in the symptom mitigation path of 
mobile community residents (IV) 
 
Based on the results, a symptom mitigation path for mobile community residents 
was created (Figure 10). The path describes the sequence of alternative events 
that may occur when a symptomatic mobile community resident uses community 
pharmacy services.  
 
 The first step in the symptom mitigation path is to choose whom to contact when 
symptoms occur. Ambulatory patients in this study managed their symptoms by: 
contacting either pharmacies or general practitioners (or other health care 
professionals); managing the symptoms on their own; or soliciting help from 
friends and relatives. In many cases pharmacies were described as a more 
convenient and flexible way of obtaining information and medicines than were 
medical doctors or other health care professionals.  They reported that 
pharmacies were easy to access and did not have long waiting hours, and that the 
services did not cost extra. Pharmacies were chosen especially in those cases 
when the focus group participant knew in advance what they wanted. They 
reported that this prior knowledge was based on their own previous experiences, 
relatives´ and friends´ advice or other health care professionals’ 
recommendations. In many cases, participants knew in advance whether it would 
be possible to buy prescription medicines without a prescription in the pharmacy 
that they used. Therefore, they found it pointless to contact a physician as they 
thought that would merely result in getting the same prescription medicine that 
they could have purchased directly from the pharmacy on their own.  
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If the participants chose to contact pharmacies, they were served either by a 
professional pharmacist or by sales clerks. The participants recounted that in 
Spanish pharmacies both pharmacists and sales clerks had sold medicines to 
them. It was not always clear to the participants whether the person serving them 
was a pharmacist or a clerk. However, those who had lived in Spain for a longer 
period had a better understanding. Although a sales clerk handled the general 
dispensing of medicines, participants realised that there was at least one 
pharmacist in every pharmacy and that the sales clerk could contact this person if 
questions or any problems arose. It was acknowledged that the salespeople were 
eager to serve, but the extent of their knowledge of medicines was questioned. 
Pharmacists, by contrast, were appreciated for their professional skills.  
 
Pharmacists may dispense either prescription medicines by a prescription or non-
prescription medicines for minor symptoms. There are other situations where the 
pharmacists` main professional assistance to patients is not a product but a 
service, e.g., advice on handling their symptoms without medicines or a 
recommendation to seek care from a physician. Among this study’s sample of 
mobile patients, it was commonly reported that in Spanish pharmacies there was 
an extra option of buying prescription medicines directly from the pharmacies 
without a prescription.  Altogether 90% of the participants reported having used 
this option. Examples of products that participants reported purchasing without a 
prescription included antibiotics, sleeping pills, Viagra®, asthma medications, 
cardiovascular medicines, psoriasis medicines and analgesics. Such purchase-
decisions were sometimes based on a physicians´ diagnosis, but other times 
based on input from the pharmacy employees or even self-diagnosis. Some 
people bought medicines for which the original physician's prescription had 
expired. Some just needed something for acute conditions. Some participants 
bought medicines in Spain to bring with them upon returning to their home country 
as the medicines were believed to be cheaper and stronger in Spain. 
Respondents appreciated the flexibility and convenience of buying prescription 
medicines directly from the pharmacy, although they noted that problems may 
occur if people do not know what to buy and if they do not receive instructions on 
how to use their medicines properly.  
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In conjunction with medication dispensing, pharmacists offered medication 
counselling so that the respondents would know how to use their medicines. 
Respondents received instructions such as how many units they should take per 
day. But too often, the medication counselling did not include information about 
possible adverse reactions or interactions with other medicines, food or alcohol. 
Lack of information was mostly explained by the lack of a common language 
between the customer and the pharmacy worker. Respondents who purchased 
prescription medicines directly from the pharmacy without a prescription reported 
that they often knew the active ingredient, but not the dosage or strength of the 
medicine.  One of the respondents’ themes is that they are expected to 
understand the instructions by themselves. Package information leaflets (PILs) 
were frequently used as the sole source of information. As many people did not 
understand the language in which the leaflet was written, they were unable to 
read them. Consequently, they consulted their friends and relatives. Responses 
identified "the grapevine" as an important source of medicine information. 
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Figure 10. Symptom mitigation path for mobile community residents 
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11 SUMMARY OF KEY FINDINGS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Conclusion based on the results 
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12 DISCUSSION 
 
 
12.1  Immigrants or mobile patients? 
 
In this study, I have concentrated on Finnish mobile community residents and 
mobile patients living in Spain. It should be noted, however, that the Finnish 
immigrants represent only a minority of the total group of migrants within the EU. 
The number of Finns living in Spain has been estimated to be from 15,000 to 
25,000, whereas about one million British people are estimated to own properties 
in Spain (Hardill et al. 2004). Regardless of the size of these and other immigrant 
groups, there are many similarities among them: they all reside in Spain, use 
Spanish healthcare services and most do not have Spanish language skills or 
speak Spanish as their native language (Gustafson 2001, Casado-Diaz et al. 
2004). Of Finnish immigrants, 43% described having at least some Spanish 
language skills.  Even though the results of this study only describe the situation 
of Finns in Spain (and other migrant groups may have their own variances), the 
results may tell us something about the role of mobile community residents within 
the EU. In Spain there is also a remarkable number of immigrants from 
developing countries that may have their own lessons to teach. 
 
Most of the Finnish immigrants in Spain were more than 55 years old (89%) and 
retired (86%). This kind of age trend also exists among studies conducted with 
other immigrant populations (Casado-Diaz et al. 2004). A large proportion of Finns 
(70%) described moving to Spain for health reasons, and 68% reported using 
public health services in Spain. As many of these people are in their "third age" 
(time period between the end of working period and old age) or are elderly and 
suffer from chronic conditions, it is not surprising that these immigrants have a 
greater need of health services than the normal/younger population.  As the 
number of mobile patients may increase in the future, it would be necessary to 
know the number and background information on these people so that these facts 
could be taken into account when planning health services.  At the moment, the 
problem is that most of the migrants within the EU are categorised as “floating 
population”, that is, they have not filled in official residence applications as they 
spend part of the year in their home country and another part in Spain. This 
population does have access to necessary public health care services by EHIC – 
the same as tourists – but they burden the local health care services with their 
unplanned needs. The improvement of these services becomes difficult if the 
number of this immigrant population is not known.  Many of these immigrants 
might have fears about formally changing their residency to Spain as they also 
spend part of the year in their country of origin. These factors should be taken into 
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consideration in the EU. It would be valuable to evaluate whether it would be 
possible to create a system in which residents could reside part of the year in 
another member state and register there as "partial residents" who would have 
access to local health care services.  This kind of system would benefit individual 
patients and would also be valuable in evaluating inter-member state healthcare 
costs.  
 
Clearly the issue of responsibility for these patients should be resolved. Should 
the floating population, or partial residents, be the responsibility of their country of 
origin or should each EU member state be required also to offer health care to all 
of their immigrants? Could there be agreements between countries that would 
count the expenses of each country by the registers of their partial residents (their 
lengths of stay and usage of services)? At the moment, the system is incomplete. 
Those countries having large numbers of immigrants may be unwilling or 
financially incapable of offering extensive services to their immigrants since even 
their current expenses are inadequately covered (Rosenmöller and Lluch 2006). 
 
 
12.2  The role of the pharmacy in the healthcare of mobile 
community residents 
 
A large number of immigrants were using public health services, but private 
pharmacy services also seemed an important part of their healthcare.  Among the 
Finnish immigrants, the pharmacy was used as the primary contact with the 
healthcare system. Participants described easy access and free services as a 
motivator for using the pharmacies. In some cases, respondents thought it to be 
waste of time to contact a medical practitioner, believing that they themselves 
knew best what was wrong with them and therefore knowing what to buy from the 
pharmacy.  Similar to practices in developing countries, the possibility of buying 
prescription-only medicines without a prescription probably has increased the use 
of pharmacies at the expense of medical practitioners (Van der Geest 1987, 
Hardon 1987, Greenhalgh 1987, Price 1989). 
 
Survey respondents found pharmacy services and the knowledge ability of the 
personnel satisfactory, even though it was not always clear whether they were in 
contact with a trained pharmacist or a clerk. In focus group discussions, some 
participants argued that pharmacy personnel could be the equivalent of 
ironmongers, that is, you get what you order at the hardware store, which is okay 
as long as you take responsibility for your choices.   
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Although the pharmacy was felt to be an important part of the immigrants’ 
healthcare experience, in many cases they found medication counselling 
dissatisfactory.  In focus group discussions respondents described the process of 
medication counselling as “they give you the medicines and tell how many times a 
day you should take them”.  But is this enough? In recent years, developed 
countries have developed advanced comprehensive pharmacy services and 
described pharmaceutical care as an important part of these pharmacy services 
(Farris et al. 2005).  These kinds of services may be offered to Spanish customers 
in Spain (Gastelurrutia et al. 2005), but the services offered to the immigrants 
there seem less comprehensive. The minimum requirement should be that the 
pharmacist/salesclerk selling the medicines should ensure that the customer does 
not have any contraindications to the products and that the customer knows how 
to use the medicine safely. When considering immigrants, many of them are 
advanced in years, suffer from chronic morbidity, and use medicines regularly. 
These factors should be taken into account in pharmacies, otherwise the 
medication safety of these immigrants may be jeopardised.  After all, it should be 
noted that pharmacists in the EU are expected to adhere to the internationally 
acknowledged professional standards of assuring high quality, safe and effective 
pharmacy services for all clients (FIP 1997, 2004).   
 
This may sound simple, but it is not. In most of the cases, immigrants and 
pharmacy personnel do not share the same language. It cannot be expected that 
all Spanish pharmacists will speak foreign languages. Therefore those member 
states having immigrants in Spain or any other mass migration area (e.g., 
Southern France) should collaborate to find solutions to tackle the problems. A 
good example of such co-operation is EMEA´s data bank, which may in the future 
provide a patient information tool to overcome some of the language barriers 
(Wagner 2005). This multilingual data bank will include a summary of product 
characteristics and patient information. Both healthcare professionals and patients 
will have access to this databank. For example, the FGDs participants in this 
study described the problem of understanding the information in PILs, which were 
written in Spanish. The databank may solve this part of the problem.  However, it 
will not solve all problems; the lack of individual medication counselling still exists 
and elderly immigrants and those with low educational skills may find this 
computer-based service difficult to use. It should also be noted, that a lack of 
information is not always the core of the problem. Nowadays people have access 
to masses of information by the Internet, but they may not know how to use this 
information properly (Peterson-Clark et al. 2004). There is always the possibility 
that, when the amount of readily available information increases, people will start 
making their own diagnoses and go directly to pharmacies to buy prescription 
medicines for their symptoms. 
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As it is predicted that the number of mobile community residents will increase in 
the future, there should be some EU-wide consideration of how to manage the 
health care of these people, especially in the mass-immigration areas.  Perhaps it 
would be possible to provide EU-funded language courses to healthcare 
professionals so that there would be at least one English-speaking professional in 
each centre. To avoid this being construed as a compulsory practice, it could be 
presented as an opportunity to develop a competitive asset. There could 
alternatively be multilingual healthcare centres in tourist areas employing 
professionals from all the EU nations having immigrants in the area.  In Spain, 
many private clinics are offering services in the customers´ native language, but 
similar services cannot be found in public clinics or pharmacies.  However, 
pharmacies have an important role in the health care of immigrants, and unless 
the practice of selling prescription medicines without a prescription suddenly 
ceases, they could well become the only healthcare units to have contact with 
patients prior to pharmacotherapy.  Therefore, pharmacy personnel should be well 
educated and able to answer the needs of their customers.  
 
 
12.3  Medication use among immigrants – how safe and rational 
is it? 
 
Most of the Finns in Spain were aware that they could buy a wide range of 
medicines directly from some pharmacies without a prescription, and some of 
them had done so. A large number (41%) of antibiotic users had bought their 
antibiotics without a prescription and also some prescription analgesics were 
bought without a prescription. In focus group discussions, participants reported 
that they had used antibiotics, sleeping pills, Viagra®, asthma medications, 
cardiovascular medicines, psoriasis medicines and painkillers without 
prescriptions. Many of these medicines were originally prescribed for them by 
their physicians, but some of the other diagnoses were made in pharmacies or by 
the customer. Does it constitute rational use of medicines when they are used 
based on a friend's or one’s own diagnosis? Participants said that it was common 
for their friends, relatives or the grapevine to have an effect on their medication 
use habits.  
 
In developed countries, pharmacies are normally seen as a stepping -stone to the 
general practitioner, and people tend to contact pharmacies to seek help for minor 
ailments (Hassell et al. 1997). In Spain, the role of pharmacy is much broader; by 
offering prescription medicines without a prescription, the pharmacist or sales 
clerk might become responsible for the overall healthcare of the patient. Patients 
are less likely to go to medical practitioners as they can gather everything they 
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need – both diagnosis and the medication – easily and directly from the 
pharmacies. But are pharmacy personnel capable of doing all this on their own? 
Pharmaceutical care in the areas of preventing drug-related problems and in 
follow-up treatment of chronically ill patients has been demonstrated to be 
effective in many studies (Chamba et al. 1999, Westerlund et al. 1999, Närhi et al. 
2000, Tully et al. 2000, Närhi et al. 2001, Schulz et al. 2001, Leemans et al. 2003, 
Van Mil 2005, Fornos et al. 2006, Mangiapane et al. 2005, Paulos et al. 2005).  
But in pharmaceutical care, most of the decisions are made in co-operation with 
different healthcare professionals, especially physicians.   
 
This kind of action may not be defined as pharmaceutical care, but what then is it 
and why are pharmacies committing to it? Most of the participants in this study 
appreciated the freedom of being able to go directly to the pharmacy. Does this 
simply mean that the Spanish pharmacy system is good at customer service? Is 
selling medicines to the foreigners merely a business matter? Some of the 
participants of this study said that they bring medicines back to Finland as some 
of the medicines (for example, strong cough medicines) are difficult to obtain from 
Finnish pharmacies as they always need an original prescription.  Good business 
or not, there should be clear control over what it means when a medicine has a 
prescription status. Within the EU, national authorities make decisions on Rx-to-
OTC switches. In Spain, “by prescription only” is printed on prescription medicine 
packets, but despite the label, the medicines can be bought without prescription in 
some pharmacies. It is an illegal, but common practice (Figueiras et al. 2000, 
Caamano Isorna et al. 2004, Barbero-Gonzalez et al. 2006, II).  The Spanish 
government has tried to enforce the regulations (Scrip 2005), but it continues to 
be a problem. 
 
These findings indicate that regulations and their enforcement can play a crucial 
role in actually assuring the rational use of medicines.  It is interesting to see that 
Finns, who are used to a strict policy with access and use of prescription 
medicines in their home country, totally change their medication use habits when 
they live in a less strictly regulated country.  However, it may not be enough to 
enforce the regulations, because as long as customers are demanding 
prescription medicines without prescription and are ready to pay for them, at least 
some pharmacies may continue to sell them. Could the competition between 
pharmacies force some to sell as much medicine as possible, even though they 
may recognise the health risks?  As mentioned in the focus group discussions, 
some pharmacists may think that they will never get caught if they sell prescription 
medicines to the foreigners. It could be that the health risks are widely recognised, 
but as long as this is not an actual problem among Spanish customers, are 
Spanish authorities supposed to take the whole responsibility or should the EU 
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assure the medication safety of mobile European citizens? Medication safety has 
been an important pharmaceutical policy issue in the Council of Europe (Council 
of Europe 2007): should medication safety for mobile patients be added to this 
agenda? Also, should the issue be more visible in the agenda of the EU. 
 
It is important to persuade customers not to buy prescription medications without 
a prescription and raise awareness of the medication safety risks related to this 
action. They may not understand that these medicines are Rx medicines and that 
there are risks related to these medicines, perhaps seeing these medicines as 
less harmful, since they were available without prescription. They may also 
assume that the medicines pose fewer risks than strictly prescription-only 
medicines. In FGDs, some participants did recognise the safety risks, but many 
thought that they knew enough to make their own decisions. There are several 
risks related to this kind of action: a person with symptoms may go to the 
pharmacy, rely on the pharmacy workers’ knowledge (who might not be a 
pharmacist) and end up using a prescription medication without getting a proper 
diagnosis or any medication counselling or instructions on how to use the product. 
 
There is no harmonised policy on community pharmacy practises within the EU, 
as each national community pharmacy system is individual and has its own 
cultural and historical roots (Vogler et al. 2006). There is no one correct system to 
which all the other systems should transform. However, there are criteria that 
professional pharmacists should meet. The WHO emphasises the pharmacist’s 
role in the rational use of medicines, and the EU has guidelines on which 
medicines can be sold without a prescription (European Commission 2006). In 
addition, the FIP emphasises the professional responsibility that pharmacists have 
to provide sound, unbiased advice and to ensure that self-medication occurs only 
when it is safe and appropriate to do so (FIP 1996, 1997).  
 
 
12.4  Theoretical considerations – advantages and limitations 
 
The pharmaceutical policy perspective was chosen for this study in order to 
investigate how community pharmacies and mobile community residents are 
taken into account in EU’s pharmaceutical policymaking. The aim was for the 
study results to raise awareness of these issues, and to be used in the 
development of pharmaceutical policies at national and EU levels. Other theories 
and approaches could have been used to study this phenomenon (e.g., 
“professions theory” or “theory of risk society”), but pharmaceutical policy was 
chosen as it has the potential to contribute to policy change.  
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Policy changes are often based on the evaluation of older policies: in this case the 
policy approach in the literature review made it possible to evaluate the strengths 
and weaknesses of older policies, and the aim of the results was to provide 
evidence in which new policies or modifications of older policies could be based 
(NSW Health Department 1998). Using the pharmaceutical policy approach gave 
a clear structure for the analysis and interpretation of results that might provide 
ideas and suggestions that can directly be applied to policy development and 
change. 
 
In the beginning of this study process, it was not clear that the pharmaceutical 
policy perspective would be chosen. In the first phase, the object of the study was 
examined using a more epidemiological approach, and the medication use of 
mobile community residents was the main focus of the study. This changed, 
however, as mobile patients became a more important part of the EU’s health 
policies. Consequently, it became clear that the pharmaceutical policy perspective 
was lacking. The policy perspective and the desire for the research to contribute 
to policy change made the study both inspiring and challenging since, based on 
the literature, there are many different stakeholders that influence actual 
policymaking and determine if there is a need for policy change. This is the 
complex situation into which the present work was introduced, with a clear 
knowledge of the way that policymakers actually frame a situation will strongly 
influence the subsequent development of policies (Traulsen and Almarsdottir 
2005c). 
 
A variety of conceptual perspectives could have been used to study this 
phenomenon and they all would have had lessons to teach. For example, it could 
have been interesting to study the patients´ help-seeking process in more depth: 
especially how the symptom mitigation process of mobile community residents 
differs from non-mobile community residents. This approach could have 
contributed to a deeper understanding about differences between these two 
groups.  With knowledge of these differences, the needs of the mobile community 
residents could have been identified and appropriate health care services could 
have been developed in the areas where mobile community residents reside.  
Although the pharmaceutical policy approach also provided valuable information 
about community pharmacy services, this approach excluded other health 
services from this study. One alternative approach would have been to study, in 
more depth, risks related to using health care services abroad. The present study 
identified several risks related to the use of community pharmacy services in 
Spain.  A risk approach could be applied in the future, in order to understand risks 
related to the use of any health care services, and possibly leading to their 
improvement and to contributing to a higher level of public health within the EU.   
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Since the 1960s, there have been two main objectives in political decisions in the 
EU regarding pharmaceutical policies, i. ensuring public health, and ii. promoting 
industrial competitiveness. However, neither community pharmacies nor mobile 
community residents are mentioned in the context of pharmaceutical policies 
(European Commission 2000b). This made it more challenging to study this 
phenomenon, as there were no previous studies, which applied the 
pharmaceutical policy approach to the understanding of medication use, the role 
of community pharmacies and the symptom mitigation process of mobile 
community residents. On the one hand, due to the lack of the previous studies, 
the literature review was mainly based on the studies conducted on non-mobile 
community residents. On the other hand, the lack of previous studies made the 
research inspiring and exciting. Studying this subject was found to be important in 
raising the awareness about a phenomenon of which there was very little previous 
knowledge.  
 
It was known that the number of mobile community residents within the EU has 
been increasing and that the developing Union with its new member states will 
face unique challenges to the development of pharmaceutical policies in the 
future. It was inspiring to follow the development of pharmaceutical and health 
care policies during these years.  During the years the study was being 
conducted, mobile patients have become an important issue in the EU’s health 
policy agenda, and their rights to health care services (other than community 
pharmacies) have been broadly discussed in this context (European Commission 
2003c, 2003d, 2004). However, the use of medicines or community pharmacy 
services has not been part of this discussion. This study provides additional 
information about the use of community pharmacies as a part of the total 
spectrum of health care services. Politicians do not always recognise community 
pharmacy services as a part of health care services, but the results of this study 
suggest that, the role of community pharmacies is important, at least in the 
symptom mitigation process of mobile community residents. One reason why 
community pharmacies are seldom mentioned in the EU’s pharmaceutical policies 
may be that health care services have been mainly the responsibility of the 
member states and have therefore received less consideration at the EU level 
(Treaty of Amsterdam 1997, Article 152, Directive 2005/36/EC). Studying this 
phenomenon from the pharmaceutical policy approach helped to clarify that 
pharmaceutical policies should consider the role of community pharmacies; that 
policy should not only be developed at the national level, and that general 
minimum standards for these services should be developed and evaluated.  
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12.5  Methodological considerations and limitations 
 
None of the study methods are absolutely accurate or non-biased. In this study 
method-triangulation was used to strengthen the study methods employed. 
However, by using several methods, it should not be assumed that weaknesses in 
one method would necessarily be compensated by strengths in another. 
Triangulation should be seen more as a way of ensuring comprehensiveness 
(Mays and Pope 2000).  
 
12.5.1 QUANTITATIVE STUDY I-III 
 
In this study, a survey questionnaire was used. Surveys are widely used in 
pharmacy practice studies as a way to obtain data from a large group of people 
and to generalise the findings to the larger population (Smith 2002). It is also 
argued that survey research requires less time and is cost-saving compared to 
individual interviews (Smith 2002). However, the survey instrument should be well 
designed in order to measure what it was intended to measure. It should be 
suitable and effective in eliciting to potential responses (Smith 2002). The length 
of the questionnaire should also be reasonable. There is always a possibility that 
some questions will be misinterpreted or that people will not be able to provide the 
information (recall bias).  Sampling procedures, sample size and response rates 
may affect the generalisability (Smith 2002). In this study, a convenience sample 
was used. A convenience sample is the selection of the most readily accessible or 
willing individuals, and it can be a useful way of collecting information on an 
otherwise difficult-to-access population (Smith 2002). However, convenience 
sampling diminishes generalisability and the value of the research, especially if 
other methods could be employed (Smith 2002).  Overall, there are many issues 
that impact on the reliability and validity of the research. 
 
Reliability 
 
Reliability means the replicability and repeatability of the results. The higher the 
quality of the method, the lesser the amount of random "noise" in the results  
(Golafshani 2003, Taanila 2006). When measuring with a reliable method, the 
results of the study should be about the same regardless of when the study was 
conducted (test-retest reliability), or who was involved in the study (inter-rater 
reliability) (Roberts and Priest 2006). Factors that might decrease the validity 
include small sample size and errors during different study periods (for example, 
misunderstanding the questions, memory biases, motivations, and the situation 
and place in which the responses were given) (Taanila 2006).  
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Although questionnaires are generally an efficient method of gathering factual 
data, it should be assured that respondents are able to provide the data asked 
(Smith 2002). When people are asked to recall events (e.g., medicine use in the 
past), answers may be inaccurate (Smith 2002). In this study, we asked about 
analgesics use relating to the preceding two-week period.  Klungel et al. (2000) 
argue that questions that ask about medications that were used during a 
preceding two-week period do tend to provide accurate information (Klungel et al. 
2000, Smith 2002). On the other hand, it has been argued that events that are 
exceptional can be remembered for a longer period of time (Smith 2002). In this 
study participants were asked about their antibiotic use during the previous six 
months. Antibiotic use was classified as a more infrequent activity, and therefore, 
it was assumed that participants would remember it for a longer period. However, 
it is always possible that some inaccuracy in the answers may have occurred. 
 
Validity 
 
Validity describes the extent to which the study has measured the aspects it was 
supposed to measure. It can be divided into external and internal validity (Tuomi 
and Sarajärvi 2003, Roberts and Priest 2006). Internal validity could be increased 
by piloting the questions (content validity), comparing the questionnaire with other 
validated measurements of the subject (criterion validity) and by demonstrating 
the relationship between the concepts under study and the theory (construct 
validity). In this study, we piloted the questionnaire with 10 people who were 
similar to the intended study participants. To increase criterion and construct 
validity, and because we had no previous validated study methods or theories 
about the subject, the questionnaire was compared with several validated 
questionnaires that measured subjects under similar themes.  
 
External validity is related to the generalisability of the results. If the sampling 
method is not valid, the findings cannot be generalised to the target population. 
An unrepresentative sample could be caused by errors in the sampling framework 
or by a low or differential response rate. Low response rates raise the issue that 
non-respondents may differ in some important or relevant way from the 
respondents; the results cannot be generalised to the whole population, but the 
respondents should be seen as a self-selected group. Non-respondents may 
include those who refused to participate, those who were unable to respond and 
those who were unable to provide the required information (Smith 2002).  Low 
response rates cannot be compensated for solely by increasing the sample size. 
In this study, the response rate was 53, which is moderate for these kinds of 
studies (Heikkilä 2001, Smith 2002).  
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 The sampling method of this study may have limited its external validity. The first 
challenge in designing the sampling method that emerged was the sampling 
frames. For a probability sampling frame, a list of the members of the population 
would have been preferable. However, there was no accurate information 
specifically about the Finns living in Spain, only estimates about their numbers as 
only a small percentage of this population is registered to the official registries.  As 
a consequence of the absence of a sampling frame, it was not feasible to take 
random samples of the Finnish people living in Spain. The sampling method 
consisted of sending out the questionnaires with newspapers and by handling out 
the questionnaires to different associations in the Costa del Sol region. The 
questionnaire distribution centres were chosen based on their location and 
function within the community. They were located in different cities in Costa del 
Sol, and they gathered people from different backgrounds, ranging from the 
wealthy/active to the underprivileged. It is possible that this method resulted in a 
biased sample, but if only the registered population were studied, it would have 
been seriously biased. In addition, it would then not have been possible to study 
the same aspects examined in this study, since the registered population (if 
retired) may get all of their medicines for free (e.g., if they have a prescription from 
a general physician working in a public health centre).  Therefore, it was assumed 
that among this population it would be uncommon to self-medicate and use the 
pharmacy as the only source of health information. In this study the main focus is 
on the role of the pharmacy and on self-medication with prescription medication. 
Therefore, by studying only those who had officially become residents, the study 
would have lost its meaning. This sampling method had been used in an earlier 
study made of Finnish immigrants in Spain (Karisto 2005). Indeed, a large number 
of the migrant studies have been conducted by using associations and 
snowballing in order to deliver questionnaires (Casado-Diaz et al. 2004). These 
surveys also were faced with the unavailability of a precise sample frame 
(Casado-Diaz et al. 2004).  
 
12.5.2 QUALITATIVE DATA (IV) 
 
Qualitative research have been criticised as lacking scientific rigour (Mays and 
Pope 1995), especially concerning limitations on the generalisability of its results. 
There are different opinions on whether qualitative study results could or even 
should be generalised (Smith 2002). Random samples are often not feasible and 
sample sizes may be too small to perform quantitative statistical analysis (Pope et 
al. 2000).  More than gathering large amounts of data, the aim of the qualitative 
study is to gather deeper information about the phenomena in  typical community 
settings (Pope and Mays 1995). Therefore, the number of focus groups interviews 
needed is not often determined at the beginning of the study, but decided based 
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on the rule of saturation (Eskola and Suoranta 1998). In qualitative research, 
generalisations are not made directly from the data, but from interpretations based 
on the data (Eskola and Suoranta 1998). Eskola and Suoranta suggest that the 
factors that influence the generalisation are the study subjects.  It is preferable 
that they share a similar world of experiences and have some background 
information on, and interest in, the study subject. In this study, these factors were 
taken into consideration in the study design. The groups themselves were 
homogenous, but we created differences in the characteristics between groups. 
By bringing together individuals who share similar characteristics, it deepens and 
adds richness to the discussions (Lehoux et al. 2006). All of the participants had 
used pharmacies and were of a similar age, though groups were gathered from 
different socio-economic backgrounds in order to elicit broader perspectives from 
the subjects and to allow for comparisons.  This also increases confidence in the 
reliability of the findings (Smith 2002). In this study, the issues that emerged in 
interviews were similar regardless of the group characteristics. Even though this 
does not strictly enable generalisation of the results, it does indicate that the 
beliefs and experiences do not represent only the views of a specific group. The 
interpretations should not be based on occasional pickings from the material, but 
to commonly reoccurring themes (Eskola and Suoranta 1998).  
 
Reliability  
 
The role of the researcher is one of the key issues affecting reliability. The 
reliability of qualitative research concerns the reproducibility of the findings, that 
is, the consistency between raters in the data collection (Smith 2002).  The 
researcher should be aware of his subjective role, as an absolute objectivity is 
impossible to reach. Therefore, using more than one researcher may increase the 
reliability of the study if they are calibrated. It is also important to keep notes of the 
decisions that have been made throughout the process (Roberts and Priest 2006). 
In order to enable the reader to assess the reliability of the study, the study design 
and analysis methods must be described in detail (Mays and Pope 1995). All of 
the records and transcribing should be made accurately and include procedures 
designed to assure the accuracy. (Roberts and Priest 2006). In this study, two 
researchers conducted the discussions, one as a moderator and the other as an 
observer and note-keeper. The same two researchers performed the analysis, in 
order to avoid bias. However, this does not assure absolute objectivity of the 
results, as both of the researchers did have some previous knowledge of the 
study subject.  
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Validity  
 
Validity is described as how well the research tool measures the study subject 
(Roberts and Priest 2006). Researcher bias may be one factor affecting the 
validity of the study. The influence of the personal characteristics of the 
researcher and their educational backgrounds should be taken into account (Mays 
and Pope 2000). It should be assured, that all the potential issues that are 
important to the participants are raised and that all identified participants are able 
to attend the discussion (Smith 2002). In this study, the sizes of focus groups 
were defined so that no one would be left out. However, the moderator has a 
major influence in guiding the conversations, and therefore it is important that the 
moderator maintain objectivity during the interviews. On the other hand, there is 
also a risk of researcher bias during the analysis. It has been discussed that it 
could be both advantageous and problematic if the researcher was familiar with 
the study subject (Roberts and Priest 2006). In this study, the researchers tried 
their best to be non-reactive and impartial during the study. On the other hand, 
previous knowledge about the subject enabled a deeper understanding of the 
outcomes of the interviews.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  110 
 
 
13 CONCLUSIONS 
 
 
 
Based on the results of this study, the following conclusions can be drawn: 
 
1. A large number of Finns in Spain are elderly and suffer from chronic 
morbidity. They are therefore assumed to have a greater need of 
healthcare services than the general population. Meeting immigrants’ 
health-service needs poses a challenge to the authorities in countries with 
high immigration rates – particularly if the immigrants are not assimilated 
into the society. This problem will grow as the number of immigrants 
continues to increase within EU countries. 
 
2. Pharmacies provide open access and may be the first and most frequent 
continuing contact that an immigrant has with a nation’s healthcare system.  
Thus, community pharmacies play a role in a nation’s primary healthcare 
system, particularly regarding relief for minor symptoms, access to 
medicines and assurance of their safe use.    
 
3. Community pharmacy services, however, did not meet all the needs of the 
immigrants, and there were several patient safety risks related to the 
actions of the pharmacies, including: 
 
a. Prescription medicine use without prescription 
b. Irrational use of medicines (e.g., needless use and use by self-
diagnosis) 
c. Language barriers between mobile community residents and 
pharmacy practitioners (pharmacists and sales clerks) 
d. Lack of medication counselling 
e. Inadequately educated pharmacy personnel taking responsibility of 
the dispensing of patients´ medications 
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13.1 Policy implications 
 
 
• All of the member states of the EU should take responsibility for promoting 
public health goals in their national policies regarding the rational use of 
medicines and medication safety. Programmes on these topics should also 
be offered to lay public. 
 
• It would be important to define the role of the pharmacy in health care, and 
there should be European-wide minimum standards for pharmacy services 
as well as detailed strategies on how these could be implemented in each 
country. 
 
• In every member state, there should be strict control over the regulations 
on which medicines can be obtained without prescription. 
 
• Mobile patients should be added to the health and pharmaceutical policy 
agenda in the EU, and plans should be made so that, in the future, the 
mobile patients are able to rely on the safety and quality of health care 
services  (including pharmacy services) in every member state. 
 
• It is important to consider where the responsibility lies for these mobile 
patients and partial residents within the EU. The member state where 
migrants reside may not have resources to take all of the responsibility. 
The present system may not meet the needs of, e.g., immigrants who 
spend part of the year in Spain and another part in their country of origin. 
 
• It would be important to more accurately estimate the number of the 
“floating population” so that they can be taken into account in planning local 
health services in the mass-immigration areas. 
 
• The language barrier seems to be a cause of medication safety risks 
among mobile patients. The options to improve the language skills of both 
immigrants and health care professionals in Spain should be considered. 
 
• The possibility of establishing EU funded multilingual healthcare centres 
and pharmacies in areas where millions of mobile community residents 
reside should also be considered. 
 
 
  112 
13.2  Further research 
 
 
This study demonstrates that there are developing issues regarding healthcare 
and community pharmacy services for mobile community residents within the EU. 
Additional study is recommended: 
 
• to understand how the healthcare of mobile patients is managed in the EU 
• to study mobile patients’ needs and their health service (including 
community pharmacy service) usage in the EU 
• to examine the origins, occurrence and outcomes of the potential problems 
that mobile patients are facing 
• to study the rationality of self-medication among mobile community 
residents 
• to examine different approaches to creating drug reimbursement systems 
for mobile community residents. 
 
These kinds of EU-wide studies could be implemented in co-operation with those 
member states that have large numbers of their citizens residing in another 
member state. The studies would be valuable for the implementation of EU-wide 
policies concerning the safety and status of mobile patients and immigrants within 
the EU. 
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APPENDICES 
 
APPENDIX 1 
 
QUESTIONNAIRE 
 
This free translation of the questionnaire does not include all the questions. 
Only questions relevant to this study were translated. 
 
 
BACKGROUND DETAILS 
 
 
Gender 
1 Male  
2 Female 
 
Year of Birth 
19__ 
 
How many winters have you stayed in Spain? 
__Winters 
 
Do you live in Spain? 
1 Around the year 
2 During winter time 
3 Few months per year 
4 Other, please define? 
_____________________________________________ 
 
Are you 
1 Single 
2 Cohabitation without marriage 
3 Married 
4 Divorced  
5 Widowed 
 
Are you living 
1 Alone 
2 Together with a spouse/partner  
3 Together with a member of your family 
4 Together with someone else 
 
Are you 
1 Working 
2 Part-time pensioner 
3 Pensioner 
4 Other, please define? 
  
 
What is your education? 
1 Elementary school 
2 Middle school 
3 Graduate 
4 Vocational school 
5 University/College/Polytechnic 
6 Other, please define? 
     _____________________________________________ 
 
What is your current/former occupation? 
_____________________________________________ 
 
Did healthcare related matters play a role in your decision to move into Spain? 
1 None 
2 Moderate 
3 Important role 
 
Do you use Spanish public healthcare services? 
1 Never 
2 Sometimes 
3 Often 
4 Always 
 
Are you able to communicate with some of the following languages (You can mark 
multiple languages)? 
1 Spanish 
2 English 
3 French 
 
 
STATE OF HEALTH 
 
How would you describe your overall state of health currently? 
1 Poor 
2 Average 
3 Good 
 
Are you suffering from any long term disease? 
1 No (Please move the question XX) 
2 Yes, what? (please list all) 
_____________________________________________ 
 
Are you a smoker? 
1 No 
2 Yes 
 
 
  
 
Have you been suffering from any of the following symptoms during the last two 
weeks? 
 
1 Chest pain during physical stress 
2 Joint ache 
3 Headache 
4 Back pain 
5 Other aches 
6 Shortness of breath 
7 Anxiety/Irritation 
8 Heartburns 
9 Constipation 
10 Other digestive tract problems 
11 Eczema 
12 Tiredness 
13 Depression 
14 Insomnia 
15 Nausea 
16 Other symptoms, please describe? 
_____________________________________________ 
 
 
SATISFACTION ON PHARMACY SERVICES 
 
 
What is better or worse in Spanish pharmacies compared to Finnish Pharmacies? 
_______________________________________________________ 
_______________________________________________________ 
 
 
Have you faced any problems when using Spanish Pharmacies? 
1 Cannot say 
2 None 
3 Yes, what kind of? 
_______________________________________________________ 
_______________________________________________________ 
 
 
How important do you think it would be to have pharmacy services in Finnish in 
Costa del Sol. 
1 Not so important 
2 Rather important 
3 Very important 
 
 
 
  
Should the Spanish Pharmacy system be developed in your opinion, so that it 
would server better your needs? 
1 No 
2 Yes, please describe how? 
_______________________________________________________ 
_______________________________________________________ 
 
How satisfied are you with the following items in Spanish Pharmacies / Services? 
Please select the most appropriate choice in questions from a-f 
 
Explanation of choices: 
1. Very unsatisfied 
2. Rather unsatisfied 
3. Neutral 
4. Rather satisfied 
5. Very satisfied 
 
a The knowledge of the personnel 
 1         2          3          4        5 
b Level of the service provided by the personnel 
 1         2          3          4        5 
c Medication counseling while purchasing prescription medication 
 1         2          3          4        5 
d Medication counseling while purchasing over the counter medication 
 1         2          3          4        5 
e Selection of medications in pharmacies 
         1         2          3          4        5 
f Language skills of personnel 
         1         2          3          4        5 
 
 
------------------------------------------------------------------------------------------------------------- 
 
Where do you purchase your long-term medications? 
1 From Spain 
2 From Finland 
3 From both countries 
4 I do not use any long term medications 
 
 
 
 
 
 
 
 
 
 
  
USE OF ANTIBIOTICS 
 
 
Have you used antibiotics during the last 6 months in Spain? 
1 Yes 
2 No ( Please move to question XX) 
3 Cannot answer (please move to question XX) 
 
For what purpose have you taken antibiotics during the last 6 months? 
1 Common cold/flu 
2 Sore throat 
3 Some types of skin infections 
4 “Tourist diarrhoea” 
5 Wound infection or a post operation condition 
6 Other, please describe? 
_______________________________________________________ 
_______________________________________________________ 
 
Do you remember the name of the antibiotics you have taken during the past 6 
months? 
0 No 
1 Yes, please write down the name 
_______________________________________________________ 
 
 
Where have you bought the antibiotics? 
0 From the pharmacy without a prescription from a doctor 
1 From the pharmacy with a prescription 
2 Both 
3 Cannot say 
 
Have you had any of the following side effects during your antibiotics treatment? 
0 No side effects 
1 Diarrhoea 
2 Stomach aches 
3 Eczema/Rash 
4 Shortness of breath 
5 Other, please define? 
_______________________________________________________ 
_______________________________________________________ 
 
How have the antibiotics affected your illness? 
1   The first course have helped 
2 I had to take two courses 
3 I had to take more than 2 courses 
4 They have had no effect 
5 Cannot say 
 
  
USE OF PAIN KILLERS 
 
 
Have you used painkillers during the last two weeks? 
1 Yes 
2 No (please move to question XX) 
3 Cannot say 
 
How often do you take painkillers? 
1 Daily 
2 Weekly 
3 Few times per month 
4 Less frequently 
5 Cannot say 
 
Do you use any painkillers continuously? 
1 No 
2 Yes, how long and which painkillers have you been using? 
_______________________________________________________ 
 
 
Which pain killers have you used during the last two weeks? 
1 Ibuprofen (Neobrufen, Nurofen, Burana) 
2 Paracetamol (Panadol, Antidol, Dolostop) 
3 Acetylsalicylic Acid (Aspirin, AAS, Adiro) 
4 Ketoprofen (Ketorin, Orudis, Ketosolan) 
5 Nimesulid (Nimed, Antifloxil, Guacan) 
6 Tramadol (Tramal, Adolonta, Tralgiol) 
7 Naproxen (Naprosyn, Pronaxen) 
8 Diclofenac (Voltaren, Dolotren) 
9 Other, please define?  
_______________________________________________________ 
 
 
Are these painkillers you use: 
1 Medications prescribed by a doctor 
2 Medications bought without a prescription 
3 Both  
4 Cannot say 
 
For which symptoms do you use painkillers? 
1 Headache 
2 Articular – or muscular pain 
3 Flu or fever 
4 Undefined pain 
5 Other, please describe? 
_______________________________________________________ 
 
  
 
Do you purchase your painkillers from? 
1 Spain 
2 Finland 
3 Both countries 
Comments: 
____________________________________________________ 
 
Do you get reimbursement from your medications or do you pay them yourself? 
1 I pay all of them by myself 
2 I pay a 10% deductible 
3 I pay a 40% deductible 
4 I get all my medication free of charge 
5 Cannot say/ don’t use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
APPENDIX 2 
 
 
INTERVIEW GUIDE 
 
 
How do you describe Spanish community pharmacies (e.g., compared to Finnish 
pharmacies)? 
 
• Number of pharmacies 
• Size of pharmacies 
• Facilities 
• Pharmacy staff (service, education) 
• Pharmacy services 
• Selling lines: medicines and other goods 
• Prescription medicines 
• Over-the-counter medicines 
 
 
Role of pharmacy 
 
• Role of pharmacy in healthcare 
• How to treat symptoms (doctor, pharmacy or some other option?) 
• Availability of services 
• Availability of medicines (Rx and OTC) 
• Medication counselling 
• Promotion of rational use of medicines 
• Success of pharmacotherapy 
• Chronic diseases and their medication treatments 
• Compliance 
• Medication safety 
• Drug-to drug interactions 
• Possible risks related to medication use 
• Reliability 
• Ethicality 
• Competition between pharmacies (if any) 
 
 
 
 
 
 
 
 
 
